APOL1 inhibitors and methods of use

By providing compounds and compositions for inhibiting APOL1 activity, the problem of APOL1-mediated disease treatment is solved, and effective treatment of APOL1-mediated disease and prevention of disease progression is achieved, especially for the kidneys of individuals with high-risk genotypes of APOL1 Health issues.

CN118946349APending Publication Date: 2024-11-12MAZE THERAPEUTICS INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380027290.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-03
Filing Date
2023-01-17
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is unable to effectively treat APOL1-mediated diseases, such as chronic renal disease and kidney transplant-related problems, and there is a lack of effective therapy for individuals with high risk genotypes of APOL1.

Method used

A compound and composition are provided for inhibiting APOL1 activity, for the treatment of APOL1-mediated diseases, including chronic renal disease and kidney transplant-related problems, and for preventing or delaying disease progression.

Benefits of technology

The compounds and compositions are able to effectively inhibit APOL1 activity, treat APOL1-mediated diseases, prevent disease progression, and delay kidney transplant-related losses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946349A_ABST
    Figure CN118946349A_ABST
Patent Text Reader

Abstract

Provided herein are compounds of Formula (II): # imgabs0 # or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. Also provided are methods of preparing a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating APOL1 mediated diseases, disorders, or conditions in an individual.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application Serial No. 63 / 300,592 filed on January 18, 2022, U.S. Provisional Application Serial No. 63 / 311,668 filed on February 18, 2022, U.S. Provisional Application Serial No. 63 / 332,553 filed on April 19, 2022, U.S. Provisional Application Serial No. 63 / 400,359 filed on August 23, 2022, and U.S. Provisional Application Serial No. 63 / 422,341 filed on November 3, 2022, which are hereby incorporated by reference in their entirety. Background of the Invention

[0004] Apolipoprotein L1 (APOL1) is a pore-forming innate immune factor that protects individuals from trypanosome parasites (Vanhamme, L. et al. Nature (2003) 422, 83-87). The secreted form of APOL1 circulates in the blood as part of a unique high-density lipoprotein (HDL) complex, known as trypanosome lytic factor (TLF) (Rifkin, MR Proc. Natl. Acad. Sci. USA. (1978) 75, 3450-3454; Raper, J. et al. Infect. Immun. (1999) 67, 1910-1916). TLF is internalized by parasites via endocytosis (Hager, KM et al. J. Cell Biol. (1994) 126, 155-167). Within trypanosomes, APOL1 forms a cationic pore, causing ion flux, swelling and ultimately lysis (Rifkin, MR Exp. Parasitol. (1984) 58, 81-93; Molina-Portela, MP et al. Mol. Biochem. Parasitol. (2005) 144, 218-226; Pérez-Morga, D. et al. Science. (2005) 309, 469-472; Thomson, R. and Finkelstein, A. Proc. Natl. Acad. Sci. USA. (2015) 112, 2894-2899).

[0005] Several Trypanosoma brucei subspecies (Tbrhodesiense and Tbgambiense) have developed resistance mechanisms to APOL1-dependent killing (Pays, E. et al. Nat. Rev. Microbiol. (2014) 12, 575-584). Positive selection generated APOL1 variants G1 (S342G, I384M) and G2 (N388Δ, Y389Δ), which are able to interfere with these resistance mechanisms (Genovese, G. et al. Science. (2010) 329, 841-845). However, individuals with any binary combination of these variants (G1 / G1, G2 / G2, or G1 / G2) are at greater risk of developing a variety of chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS), kidney disease caused by hypertension, human immunodeficiency virus-associated nephropathy (HIVAN) (Genovese, G. et al. Science. (2010) 329, 841-845; Tzur, S. et al. Hum. Genet. (2010) 128, 345-350; Kopp, JB et al. J. Am. Soc. Nephro l. (2011) 22, 2129-2137), sickle cell nephropathy (Ashley-Koch, AE et al. Br. J. Haematol. (2011) 155, 386-394), lupus nephritis (Freedman, BI et al. Arthritis Rheumatol. (2014) 66, 390-396) and increased rate of decline in glomerular filtration rate (GFR) in diabetic kidney disease (Parsa, A. et al. N. Engl. J. Med. (2013) 369, 2183-2196). APOL1 high-risk genotypes are also associated with COVID-19-related nephropathy and other viral nephropathy (Shetty, A. et al. J. Am. Soc. Nephrol. (2021) 32, 33-40; Chang, JH et al. Am. J. Kidney Dis. (2019) 73, 134-139). Furthermore, decreased renal allograft survival has been observed following deceased donor kidney transplantation from donors with a high-risk APOL1 genotype (Freedman, BI et al. Transplantation. (2016) 100, 194-202).In addition, having two APOL1 risk alleles increases the risk of preeclampsia (Reidy, KJ et al. Am. J. Hum. Genet. (2018) 103, 367-376) and sepsis (Chaudhary, NS et al. Clin. J. Am. Soc. Nephrol. (2019) 14, 1733-1740). There are no approved therapies for APOL1-related nephropathy, and patients are treated with standard care based on their underlying form of chronic kidney disease. This suggests that there is a clear unmet need for therapies targeting people with a high-risk genotype for APOL1.

[0006] Numerous studies have shown that APOL1 risk variants are toxic when overexpressed in human cells (Wan, G. et al. J. Biol. Chem. (2008) 283, 21540-21549; Lan, X. et al. Am. J. Physiol. Renal Physiol. (2014) 307, F326-F336; Olabisi, OA et al. Proc. Natl. Acad. Sci. USA. (2016) 113, 830-837; Ma, L. et al. J. Am. Soc. Nephrol. (2017) 28, 1093-1105; Lannon, H. et al. Kidney Int. (2019) 96, 1303-1307). Recent findings suggest that this toxicity is associated with APOL1 pore function (Giovinazzo, JA et al. eLife. (2020) 9, e51185). Therefore, there is a need to develop compounds suitable for inhibiting APOL1 activity and methods for inhibiting APOL1 activity using such compounds. Summary of the invention

[0007] The present disclosure describes compounds and compositions that can be used to treat APOL1-mediated diseases, including a variety of chronic kidney diseases, such as FSGS, kidney disease caused by hypertension, HIVAN, sickle cell nephropathy, lupus nephritis, diabetic kidney disease, viral nephropathy, COVID-19-related kidney disease, and APOL1-related kidney disease. The compounds and compositions can treat other APOL1-mediated conditions, such as preeclampsia and sepsis. In addition, for individuals with an APOL1 high-risk genotype, the disclosed compounds can prevent the onset of non-diabetic kidney disease and / or delay the progression of any form of chronic kidney disease. The disclosed chemical substances can also prevent and / or delay progressive renal allograft loss in patients receiving kidney transplants from donors with high-risk APOL1 genotypes.

[0008] In one aspect, provided is a compound of formula (II):

[0009]

[0010] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

[0011] m is an integer from 0 to 4;

[0012] n is an integer from 0 to 2;

[0013] p is an integer from 0 to 10;

[0014] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy and C 1-6 The group consisting of alkyl groups, wherein

[0015] R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and

[0016] R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups;

[0017] R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein

[0018] R 2 The C 1-6 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and

[0019] R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH;

[0020] If it exists, then R 3 It is C 1-6 alkyl;

[0021] L 1 It is C 1-6 Alkylene, wherein

[0022] L 1 The C 1-6 The alkylene group is optionally substituted with one or more deuterium or C 1-6 alkyl substituted, and wherein

[0023] The C 1-6The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution;

[0024] L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and

[0025] Choose one of the following:

[0026] (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein

[0027] L 3 The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution,

[0028] L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, where

[0029] The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and

[0030] L 3 The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substitution;

[0031] X 1 and X 2 are each independently N or C(R 5 );and

[0032] R 4 yes:

[0033] (i)-S(O) 2 -R a ;

[0034] (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution;

[0035] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O)2 -R a ,in

[0036] R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0037] (iv)-NS(O)-(C 1-6 alkyl) 2 , wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0038] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 Alkyl or 3-10 membered heterocyclic ring, wherein

[0039] R e The 3-10 membered heterocyclic ring is optionally substituted by one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein

[0040] The 3-10 membered heterocyclic group is optionally substituted with one or more halogen, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0041] (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a replace,

[0042] (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl),

[0043] (viii) -CN,

[0044] (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 6,

[0045] (x)-C(O)-C 1-6 Alkyl, or

[0046] (xi)-P(O)(C 1-6 alkyl) 2 ;

[0047] or

[0048] (2)L 3 does not exist; and

[0049] X 1 and X 2 One of them is N or C (R 5 );and

[0050] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein

[0051] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Replace, where

[0052] R b independently selected at each occurrence from -OH, halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0053] R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 is substituted with a cycloalkyl radical, and wherein

[0054] R b The C 1-6 The C of the alkyl group 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 alkyl or -OH substituted, and

[0055] R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 alkyl substituted, and wherein

[0056] R bThe C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide, and

[0057] The 5-20 membered heteroaryl group is optionally substituted by one or more R c Replace, where

[0058] R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0059] R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution,

[0060] R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, and

[0061] R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 alkyl substituted, and wherein

[0062] R c The C of the 3-10 membered heterocyclic group 1-6 The alkyl group is further optionally substituted with one or more -OH groups;

[0063] R a independently at each occurrence is:

[0064] (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution,

[0065] (ii)C 3-10Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, where

[0066] The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0067] (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substituted, or

[0068] (iv)NH(C 1-6 alkyl);

[0069] R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where

[0070] R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo groups or -OH, and

[0071] R 5 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups;

[0072] X 3 is N or C (R 6 );

[0073] X 4 is N or C (R 7 );

[0074] and

[0075] R 6 and R 7 Each is independently H or halo.

[0076] In one aspect, provided is a compound of formula (I'):

[0077]

[0078] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

[0079] m is an integer from 0 to 4;

[0080] n is an integer from 0 to 2;

[0081] p is an integer from 0 to 10;

[0082] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy or C 1-6 The group consisting of alkyl groups, wherein

[0083] R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and

[0084] R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups;

[0085] R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein

[0086] R 2 The C 1-6 The alkyl group is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and

[0087] R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH;

[0088] If it exists, then R 3 It is C 1-6 alkyl;

[0089] L 1 It is C 1-6 Alkylene, where L 1 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 alkyl substituted, and wherein the C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution;

[0090] L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and

[0091] Choose one of the following:

[0092] (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein

[0093] The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution,

[0094] L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, and

[0095] The 3-10 membered heterocyclyl is optionally substituted with one or more -OH;

[0096] X 1 and X 2 are each independently N or C(R 5 );and

[0097] R 4 yes:

[0098] (i)-S(O) 2 -R a ;

[0099] (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution;

[0100] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0101] (iv)-NS(O)-(C 1-6 alkyl) 2 , wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0102] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6alkyl or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0103] (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a replace,

[0104] (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl),

[0105] (viii) -CN,

[0106] (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 6,

[0107] (x)-C(O)-C 1-6 Alkyl, or

[0108] (xi)-P(O)(C 1-6 alkyl) 2 ;

[0109] or

[0110] (2)L 3 does not exist; and

[0111] X 1 and X 2 One of them is N or C (R 5 );and

[0112] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein

[0113] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Substitution, where R b is independently selected at each occurrence from halo, oxo, C 1-6Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0114] R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 is cycloalkyl substituted, and

[0115] Where R b The C 1-6 The C of the alkyl 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 alkyl or -OH substituted, and

[0116] R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 Alkyl substituted, and

[0117] Where R b The C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH groups, and

[0118] The 5-20 membered heteroaryl group is optionally substituted by one or more R c Substitution, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0119] R c The C 1-6The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution,

[0120] R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution,

[0121] And R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substituted, and

[0122] Where R c The C of the 3-10 membered heterocyclic group 1-6 The alkyl group is further optionally substituted with one or more -OH groups;

[0123] R a independently at each occurrence is:

[0124] (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution,

[0125] (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, or

[0126] (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substitution;

[0127] R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5The C 1-6 The alkoxy group is optionally substituted with one or more halo groups; and

[0128] R 6 and R 7 Each is independently H or halo.

[0129] In one aspect, there is provided a compound of formula (I):

[0130]

[0131] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

[0132] m is an integer from 0 to 4;

[0133] n is an integer from 0 to 2;

[0134] p is an integer from 0 to 10;

[0135] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy or -C 1-6 The group consisting of alkyl groups, wherein

[0136] R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and

[0137] R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups;

[0138] R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein

[0139] R 2 The C 1-6 The alkyl group is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and

[0140] R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH;

[0141] If it exists, then R 3 It is C 1-6 alkyl;

[0142] L 1 It is C 1-6Alkylene, where L 1 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 alkyl substituted, and wherein the C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution;

[0143] L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and

[0144] Choose one of the following:

[0145] (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein

[0146] L 3 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 Alkyl substituted, and

[0147] The 3-10 membered heterocyclyl is optionally substituted with one or more -OH;

[0148] X 1 and X 2 are each independently N or C(R 5 );and

[0149] R 4 yes:

[0150] (i)-S(O) 2 -R a ,

[0151] (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution,

[0152] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0153] (iv)-NS(O)-(C 1-6 alkyl) 2 , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0154] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 alkyl or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0155] (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl or oxo substituted,

[0156] (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl), or

[0157] (viii) -CN;

[0158] or

[0159] (2)L 3 does not exist; and

[0160] X 1 and X 2 One of them is N or C (R 5 );and

[0161] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein

[0162] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Substitution, where R b is independently selected at each occurrence from halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0163] R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH or -S(O) 2 -C 1-6 Alkyl substituted, and

[0164] R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH groups, and

[0165] The 5-20 membered heteroaryl group is optionally substituted by one or more R c Substitution, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0166] R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substituted, and

[0167] R c The C 3-10 Cycloalkyl is optionally substituted with one or more -OH;

[0168] R a independently at each occurrence is:

[0169] (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C1-6 Alkyl substituted, or

[0170] (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, or

[0171] (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substitution;

[0172] R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 The alkoxy group is optionally substituted with one or more halo groups; and

[0173] R 6 and R 7 Each is independently H or halo.

[0174] Any embodiment or any variation or embodiment of a compound of formula (I) or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing provided herein is also an embodiment or any variation or embodiment of a compound of formula (I') or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0175] Any embodiment or any variation or embodiment of a compound of formula (I) or formula (I') or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing provided herein is also an embodiment or any variation or embodiment of a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing.

[0176] In one aspect, provided herein is a compound of formula (IA):

[0177]

[0178] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: n is 1 or 2; and wherein m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , X 1 , X 2 , R 6 and R 7 As defined elsewhere herein. In another variation, m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , X 1 , X 2 , R 6 and R 7 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0179] In one aspect, provided herein is a compound of formula (IB):

[0180]

[0181] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , R 5 , R 6 and R 7 As defined elsewhere herein. In another variation, m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , R 5 , R 6 and R 7 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0182] In one aspect, provided herein is a compound of formula (IC):

[0183]

[0184] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 and R 5 As defined elsewhere herein. In another variation, m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 and R 5 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0185] In one aspect, provided herein is a compound of formula (ID):

[0186]

[0187] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, p, R 1 , R 2 , R 3 , L 1 , L 3 and R 4 As defined elsewhere herein. In another variation, m, p, R 1 , R 2 , R 3 , L 1 , L 3 and R 4 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0188] In one aspect, provided herein is a compound of formula (IE):

[0189]

[0190] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, p, R 1 , R 2 , R3 , L 1 , X 2 , R 6 , R 7 and Ring A are as defined elsewhere herein. In another variation, m, p, R 1 , R 2 , R 3 , L 1 , X 2 , R 6 , R 7 and Ring A are as defined for a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0191] In one aspect, provided herein is a compound of formula (IF):

[0192]

[0193] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, p, R 1 , R 2 , R 3 , L 1 , R 5 and Ring A are as defined elsewhere herein. In another variation, m, p, R 1 , R 2 , R 3 , L 1 , R 5 and Ring A are as defined for a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0194] In one aspect, provided herein is a compound of formula (IG):

[0195]

[0196] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, p, R 1 , R 2 , R 3 , L 1 and Ring A are as defined elsewhere herein. In another variation, m, p, R 1 , R 2 , R 3 , L 1and Ring A are as defined for a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0197] In one aspect, provided herein is a compound of formula (II-A):

[0198]

[0199] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, p, R 1 , R 2 , R 3 , L 1 , X 2 , X 3 , X 4 and Ring A are as defined elsewhere herein.

[0200] In one aspect, provided herein is a pharmaceutical composition comprising (i) a compound of formula (I) or any embodiment or variation thereof, such as a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a pharmaceutical composition comprising (i) a compound of formula (I') or any embodiment or variation thereof, such as a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a pharmaceutical composition comprising (i) a compound of Formula (II) or any embodiment or variation thereof, such as a compound of Formula (I), (I'), (IA), (IB), (IC), (ID), (IE), (IF), (IG) or (II-A), or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0201] In one aspect, provided herein is a method of modulating APOL1 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of Formula (I) or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or to a pharmaceutical composition comprising (i) a compound of Formula (I) or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of modulating APOL1 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of Formula (I') or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or to a pharmaceutical composition comprising (i) a compound of Formula (I') or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of modulating APOL1 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of Formula (II) or any embodiment or variation thereof, such as a compound of Formula (I), (I'), (IA), (IB), (IC), (ID), (IE), (IF), (IG), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or to a pharmaceutical composition comprising (i) a compound of Formula (II) or any embodiment or variation thereof, such as a compound of Formula (I), (II), (IA), (IB), (IC), (ID), (IE), (IF), (IG), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0202] In one aspect, provided herein is a method of inhibiting APOL1 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of Formula (I) or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or to a pharmaceutical composition comprising (i) a compound of Formula (I) or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of inhibiting APOL1 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of Formula (I') or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or to a pharmaceutical composition comprising (i) a compound of Formula (I) or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of inhibiting APOL1 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of Formula (II) or any embodiment or variation thereof, such as a compound of Formula (I), (I'), (IA), (IB), (IC), (ID), (IE), (IF), (IG), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or to a pharmaceutical composition comprising (i) a compound of Formula (II) or any embodiment or variation thereof, such as a compound of Formula (I), (I'), (IA), (IB), (IC), (ID), (IE), (IF), (IG), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0203] In one aspect, provided herein is a method of treating an APOL1-mediated disease, condition, or disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I), or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising: (i) a compound of Formula (I), or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of treating an APOL1-mediated disease, condition, or disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I'), or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising: (i) a compound of Formula (I'), or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of treating an APOL1-mediated disease, condition, or disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (II), or any embodiment or variation thereof, such as a compound of Formula (I), (I'), (IA), (IB), (IC), (ID), (IE), (IF), (IG), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising: (i) a compound of Formula (II), or any embodiment or variation thereof, such as a compound of Formula (I), (I'), (IA), (IB), (IC), (ID), (IE), (IF), (IG), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0204] In one aspect, provided herein is a kit comprising (i) a compound of Formula (I), or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof. In another variation, provided herein is a kit comprising (i) a compound of Formula (I'), or any embodiment or variation thereof, such as a compound of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof. In another variation, provided herein is a kit comprising (i) a compound of Formula (II) or any embodiment or variation thereof, such as a compound of Formula (I), (I'), (IA), (IB), (IC), (ID), (IE), (IF), (IG), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for treating an APOL1-mediated disease, disorder, or condition in a subject in need thereof.

[0205] In one aspect, provided herein are methods for preparing a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In another variation, provided herein are methods for preparing a compound of formula (I'), or any embodiment or variation thereof, such as a compound of formula (I), (IA), (IB), (IC), (ID), (IE), (IF), or (IG), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In another variation, provided herein are methods for preparing a compound of formula (I'), or any embodiment or variation thereof, such as a compound of formula (I), (I'), (IA), (IB), (IC), (ID), (IE), (IF), (IG), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. DETAILED DESCRIPTION

[0206] Unless expressly stated otherwise, the terms "a" or "an" or the like refer to one or more.

[0207] As used herein, "about" a parameter or value includes and describes the parameter or value itself. For example, "about X" includes and describes X itself.

[0208] "Subject" refers to a mammal and includes humans and non-human mammals. Examples of subjects include, but are not limited to, some primates and humans. In some embodiments, the subject refers to a human.

[0209] As used herein, an individual "at risk" refers to an individual who is at risk of developing a disease or disorder. An individual "at risk" may or may not have a detectable disease or disorder, and may or may not have shown detectable disease prior to the treatment methods described herein. "At risk" means that the individual has one or more so-called risk factors, which are measurable parameters associated with the development of a disease or disorder and are known in the art. An individual with one or more of these risk factors has a higher probability of developing a disease or disorder than an individual without these risk factors.

[0210] "Treatment" or "treating" is a method for obtaining beneficial or desired results (including clinical results). Beneficial or desired results may include one or more of the following: reducing one or more symptoms caused by a disease or disorder; reducing the extent of a disease or disorder; slowing or arresting the development of one or more symptoms associated with a disease or disorder (e.g., stabilizing the disease or disorder, preventing or delaying the worsening or progression of the disease or disorder); and relieving the disease, such as by causing regression of clinical symptoms (e.g., improving the disease state, enhancing the effect of another drug, delaying the progression of the disease, improving the quality of life and / or prolonging survival).

[0211] As used herein, "delaying" the development of a disease or disorder means postponing, hindering, slowing, retarding, stabilizing and / or slowing the development of the disease or disorder. Depending on the history of the disease and / or the individual being treated, such delay may be of varying lengths. As will be apparent to one skilled in the art, a sufficient or significant delay may actually encompass prevention, in that the individual does not develop the disease or disorder.

[0212] As used herein, the term "therapeutically effective amount" or "effective amount" means an amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof that is sufficient to achieve treatment when administered to an individual. As understood in the art, an effective amount can be one or more doses, for example, a single dose or multiple doses may be required to achieve a desired therapeutic endpoint. An effective amount can be considered in the context of administering one or more therapeutic agents, and if, in combination with one or more other agents, a desired or beneficial result can be achieved or achieved, then a single dose can be considered to be administered in an effective amount.

[0213] As used herein, "unit dosage form" refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of the active ingredient or compound, which may be in a pharmaceutically acceptable carrier.

[0214] As used herein, "pharmaceutically acceptable" means a material that is biologically or otherwise desirable, for example, a material that can be incorporated into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects.

[0215] As used herein, the term "alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, an alkyl group has 1-20 carbon atoms (i.e., C 1-20 alkyl), 1-16 carbons (i.e., C 1-16 alkyl), 1-12 carbons (i.e., C 1-12 alkyl), 1-10 carbons (i.e., C 1-10 alkyl), 1-8 carbons (i.e., C 1-8 alkyl), 1-6 carbons (i.e., C 1-6 alkyl), 1-4 carbons (i.e., C 1-4 alkyl) or 1-3 carbons (i.e., C 1-3 Alkyl). Examples of alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a particular number of carbon atoms is named by a chemical name or molecular formula, all possible isomers having that number of carbon atoms may be encompassed - for example, "butyl" includes n-butyl, sec-butyl, isobutyl, and tert-butyl; and "propyl" includes n-propyl and isopropyl. Certain commonly used alternative names may be used and will be understood by those of ordinary skill in the art. For example, a divalent group, such as a divalent "alkyl", may be referred to as an "alkylene".

[0216] As used herein, the term "alkoxy" refers to an -O-alkyl moiety. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0217] As used herein, the term "aryl" refers to a fully unsaturated carbocyclic moiety. The term "aryl" encompasses monocyclic and polycyclic fused ring moieties. As used herein, aryl encompasses ring moieties that contain, for example, 6 to 20 ring carbon atoms (i.e., C 6-20 aryl), 6 to 16 ring carbon atoms (i.e., C 6-16 aryl), 6 to 12 ring carbon atoms (i.e., C 6-12 aryl) or 6 to 10 ring carbon atoms (i.e., C 6-10 Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, fluorenyl, and anthracenyl.

[0218] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated carbocyclic moiety. The term "cycloalkyl" encompasses monocyclic and polycyclic moieties, wherein the polycyclic moieties may be fused, branched or spirocyclic. Cycloalkyl includes cycloalkenyl groups, wherein the ring moiety contains at least one ring double bond. Cycloalkyl includes any polycyclic carbocyclic moiety containing at least one non-aromatic ring, regardless of the point of attachment to the rest of the molecule. As used herein, cycloalkyl includes rings containing, for example, 3 to 20 ring carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 16 ring carbon atoms (i.e., C 3-16 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), 3 to 6 ring carbon atoms (i.e., C 3-6 cycloalkyl) or 3 to 5 ring carbon atoms (i.e., C 3-5 Cycloalkyl). Monocyclic cycloalkyl ring moieties include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, etc. In addition, cycloalkyl also includes spirocycloalkyl ring moieties, for example, spiro[2.5]octyl, spiro[4.5]decyl, or spiro[5.5]undecyl.

[0219] As used herein, the term "halo" refers to an atom occupying Group VIIA of the Periodic Table of the Elements and includes fluorine (fluoro), chlorine (chloro), bromine (bromo), and iodine (iodo).

[0220] As used herein, the term "heteroaryl" refers to an aromatic (completely unsaturated) ring moiety, which includes one or more ring heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. The term "heteroaryl" includes monocyclic and polycyclic condensed ring moieties. As used herein, heteroaryl includes, for example, 5 to 20 ring atoms (i.e., 5-20 yuan heteroaryl), 5 to 16 ring atoms (i.e., 5-16 yuan heteroaryl), 5 to 12 ring atoms (i.e., 5-12 yuan heteroaryl), 5 to 10 ring atoms (i.e., 5-10 yuan heteroaryl), 5 to 8 ring atoms (i.e., 5-8 yuan heteroaryl) or 5 to 6 ring atoms (i.e., 5-6 yuan heteroaryl). Any monocyclic or polycyclic aromatic ring moiety comprising one or more ring heteroatoms is considered as heteroaryl, regardless of the point of attachment to the rest of the molecule (i.e., the heteroaryl moiety can be connected to the rest of the molecule by any ring carbon or any ring heteroatom of the heteroaryl moiety). Examples of heteroaryl groups include, but are not limited to, acridinyl, benzimidazolyl, benzindolyl, benzofuranyl, benzonaphthofuranyl, benzoxazolyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl, furanyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, Naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxo pyridinyl, 1-oxo pyrimidinyl, 1-oxo pyrazinyl, 1-oxo pyridazinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolyl, quinuclidinyl, isoquinolyl, triazolyl, tetrazolyl and triazinyl. Examples of fused heteroaryl rings include, but are not limited to, quinolyl, isoquinolyl, benzo[b]thienyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl and imidazo[1,5-a]pyridinyl, wherein the heteroaryl can be bound via any one ring of the fused system.

[0221] As used herein, the term "heterocyclyl" refers to a saturated or partially unsaturated ring portion comprising one or more ring heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. The term "heterocyclyl" includes monocyclic and polycyclic moieties, wherein the polycyclic moieties can be fused, bridged or spirocyclic. Any non-aromatic monocyclic or polycyclic moiety comprising at least one ring heteroatom is considered a heterocyclyl, regardless of the point of attachment to the rest of the molecule (i.e., the heterocyclyl moiety can be connected to the rest of the molecule by any ring carbon or any ring heteroatom of the heterocyclyl moiety). In addition, the term heterocyclyl is intended to encompass any polycyclic moiety comprising at least one ring heteroatom, wherein the polycyclic moiety comprises at least one non-aromatic ring, regardless of the point of attachment to the rest of the molecule. As used herein, a heterocyclyl group contains, for example, 3 to 20 ring atoms (i.e., a 3-20 membered heterocyclyl), 3 to 16 ring atoms (i.e., a 3-16 membered heterocyclyl), 3 to 12 ring atoms (i.e., a 3-12 membered heterocyclyl), 3 to 10 ring atoms (i.e., a 3-10 membered heterocyclyl), 3 to 8 ring atoms (i.e., a 3-8 membered heterocyclyl), 3 to 6 ring atoms (i.e., a 3-6 membered heterocyclyl), 3 to 5 ring atoms (i.e., a 3-5 membered heterocyclyl), 5 to 8 ring atoms (i.e., a 5-8 membered heterocyclyl), or 5 to 6 ring atoms (i.e., a 5-6 membered heterocyclyl). Examples of heterocyclic groups include, for example, azetidinyl, azepine, benzodioxolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyrone, benzofuranone, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, furanone, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, , octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiophenyl (i.e., thienyl), thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Examples of spiroheterocyclyl rings include, but are not limited to, bicyclic and tricyclic systems such as oxabicyclo[2.2.2]octyl, 2-oxa-7-azaspiro[3.5]nonyl, 2-oxa-6-azaspiro[3.4]octyl, and 6-oxa-1-azaspiro[3.3]heptyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, wherein the heterocyclyl may be attached via either ring of the fused system.

[0222] As used herein, the term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur. Thus, the term "optionally substituted" implies that any one or more (e.g., 1, 2, 1 to 5, 1 to 3, 1 to 2, etc.) hydrogen atoms on the specified atom or moiety or group may or may not be replaced by an atom or moiety or group other than hydrogen. By way of illustration only and not limitation, the phrase "methyl optionally substituted with one or more chlorine" includes -CH 3 、-CH 2 Cl, -CHCl 2 and -CCl 3 part.

[0223] It should be understood that aspects and embodiments described herein as "comprising" include "consisting of the embodiment" and "consisting essentially of the embodiment."

[0224] As used herein, the term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of a given compound and is biologically or otherwise desirable. "Pharmaceutically acceptable salts" include, for example, salts formed with inorganic acids and salts formed with organic acids. In addition, if the compounds described herein are obtained as acid addition salts, the free base can be obtained by alkalizing a solution of the acid salt. On the contrary, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, can be produced according to conventional procedures for preparing acid addition salts from base compounds by dissolving the free base in a suitable organic solvent and treating the solution with an acid. Such compositions are well known in the pharmaceutical field. See, for example, Handbook of Pharmaceutical Salts Properties, Selection, and Use, International Union of Pure and Applied Chemistry, John Wiley & Sons (2008), which is incorporated herein by reference. Those skilled in the art will recognize various synthetic methods that can be used to prepare pharmaceutically acceptable non-toxic addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Salts obtained from inorganic acids include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Salts obtained from organic acids include, for example, acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, trifluoroacetic acid, etc. Similarly, pharmaceutically acceptable alkali addition salts can be prepared from inorganic bases or organic bases. Salts obtained from inorganic bases include (for example only) sodium salts, potassium salts, lithium salts, aluminum salts, ammonium salts, calcium salts, and magnesium salts. Salts obtained from organic bases include, but are not limited to, salts of primary amines, secondary amines, and tertiary amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0225] Isotopically labeled forms of the compounds depicted herein can be prepared. Isotopically labeled compounds have structures depicted herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O.17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 36 Cl, 123 I and 125 I. In some embodiments, compounds of formula (I) or formula (I') are provided, wherein one or more hydrogens are replaced with deuterium or tritium.

[0226] Some compounds provided herein can exist as tautomers. Tautomers are in equilibrium with each other. As an illustration, compounds containing amides can be in equilibrium with imidic acid tautomers. No matter which tautomer is shown and no matter how the equilibrium properties between the tautomers are, it will be understood by those of ordinary skill in the art that compounds of the present disclosure comprise amides and imidic acid tautomers. Therefore, for example, compounds containing amides are to be understood to include their imidic acid tautomers. Similarly, compounds containing imidic acid are to be understood to include their amide tautomers.

[0227] Also provided herein are prodrugs of the compounds described herein, or pharmaceutically acceptable salts thereof. Prodrugs are compounds that can be administered to an individual and release the compound described herein as a parent drug compound in vivo. It should be understood that prodrugs can be prepared by modifying functional groups on the parent drug compound so that such modifications are cleaved in vivo to release the parent drug compound. The development of prodrug compounds is well known in the pharmaceutical field. See, for example, Rautio, J., Kumpulainen, H., Heimbach, T. et al. Prodrugs: design and clinical applications. Nat. Rev. Drug. Discov. 7, 255-270 (2008), which is incorporated herein by reference.

[0228] The compounds of the present disclosure, or their pharmaceutically acceptable salts, may include asymmetric centers and thus may give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined by absolute stereochemistry as (R)- or (S)- (or, for amino acids, as (D)- or (L)-). The present disclosure is intended to include all such possible isomers, as well as their racemic and optically pure forms and mixtures thereof in any ratio. Optically active (+) and (-), (R)- and (S)- or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or may be resolved using conventional techniques, such as chromatography and / or distributed crystallization. Conventional techniques for preparing / separating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC) or chiral supercritical fluid chromatography (SFC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the disclosure include both E and Z geometric isomers. Likewise, cis and trans are used in their conventional sense to describe relative spatial relationships.

[0229] "Stereoisomers" refer to compounds composed of the same atoms bonded by the same bonds, but with different three-dimensional structures that are not interchangeable. The present disclosure encompasses various stereoisomers or mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose structures are non-superimposable mirror images of each other. "Diastereomers" are stereoisomers that have at least two asymmetric atoms, but are not mirror images of each other.

[0230] Where a given structure exists in enantiomeric and / or diastereomeric forms, a parallel bond indicates that all stereoisomeric forms of the depicted structure are possible, e.g.

[0231]

[0232] Where enantiomeric forms exist for a given structure, the presence of a parallel bond and a "*" symbol indicates that the composition consists of at least 90% (by weight) of a single isomer of unknown absolute stereochemistry, e.g.

[0233]

[0234] In cases where a given structure having two or more stereocenters exists in enantiomeric and / or diastereomeric forms, the presence of a parallel bond and two or more "*" symbols indicates that the composition consists of at least 90% (by weight) of a single enantiomer or diastereomer of unknown absolute stereochemistry, e.g.

[0235]

[0236] Where a given structure exists in enantiomeric and / or diastereomeric forms, a dashed or wedge-shaped line indicates that the composition is composed of at least 90% (by weight) of a single enantiomer or diastereomer of known relative or absolute stereochemistry, e.g.

[0237]

[0238] The abbreviations used are conventional in the art and are in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Edition, which is hereby incorporated herein by reference in its entirety. The following examples are intended to be illustrative only and are not intended to be limiting in any way.

[0239]

[0240]

[0241] Compound

[0242] Provided herein are compounds of formula (II):

[0243]

[0244] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

[0245] m is an integer from 0 to 4;

[0246] n is an integer from 0 to 2;

[0247] p is an integer from 0 to 10;

[0248] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy and C 1-6 The group consisting of alkyl groups, wherein

[0249] R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and

[0250] R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups;

[0251] R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein

[0252] R 2 The C 1-6 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and

[0253] R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH;

[0254] If it exists, then R 3 It is C 1-6 alkyl;

[0255] L 1 It is C 1-6 Alkylene, wherein

[0256] L 1 The C 1-6 The alkylene group is optionally substituted with one or more deuterium or C 1-6 alkyl substituted, and wherein

[0257] The C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution;

[0258] L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and

[0259] Choose one of the following:

[0260] (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein

[0261] L 3 The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution,

[0262] L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, where

[0263] The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and

[0264] L 3The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substitution;

[0265] X 1 and X 2 are each independently N or C(R 5 );and

[0266] R 4 yes:

[0267] (i)-S(O) 2 -R a ;

[0268] (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution;

[0269] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a ,in

[0270] R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0271] (iv)-NS(O)-(C 1-6 alkyl) 2 , wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0272] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 Alkyl or 3-10 membered heterocyclic ring, wherein

[0273] R e The 3-10 membered heterocyclic ring is optionally substituted by one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein

[0274] The 3-10 membered heterocyclic group is optionally substituted with one or more halogen, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2-R a replace,

[0275] (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a replace,

[0276] (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl),

[0277] (viii) -CN,

[0278] (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 6,

[0279] (x)-C(O)-C 1-6 Alkyl, or

[0280] (xi)-P(O)(C 1-6 alkyl) 2 ;

[0281] or

[0282] (2)L 3 does not exist; and

[0283] X 1 and X 2 One of them is N or C (R 5 );and

[0284] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein

[0285] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Replace, where

[0286] R b independently selected at each occurrence from -OH, halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a, C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0287] R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 is substituted with a cycloalkyl radical, and wherein

[0288] R b The C 1-6 The C of the alkyl group 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 alkyl or -OH substituted, and

[0289] R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 alkyl substituted, and wherein

[0290] R b The C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide, and

[0291] The 5-20 membered heteroaryl group is optionally substituted by one or more R c Replace, where

[0292] R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0293] R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution,

[0294] R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C1-6 Alkyl substituted, and

[0295] R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 alkyl substituted, and wherein

[0296] R c The C of the 3-10 membered heterocyclic group 1-6 The alkyl group is further optionally substituted with one or more -OH groups;

[0297] R a independently at each occurrence is:

[0298] (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution,

[0299] (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, where

[0300] The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0301] (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substituted, or

[0302] (iv)NH(C 1-6 alkyl);

[0303] R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where

[0304] R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo groups or -OH, and

[0305] R 5The C 1-6 The alkoxy group is optionally substituted with one or more halo groups;

[0306] X 3 is N or C (R 6 );

[0307] X 4 is N or C (R 7 );

[0308] and

[0309] R 6 and R 7 Each is independently H or halo.

[0310] Provided herein are compounds of formula (I'):

[0311]

[0312] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

[0313] m is an integer from 0 to 4;

[0314] n is an integer from 0 to 2;

[0315] p is an integer from 0 to 10;

[0316] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy or C 1-6 The group consisting of alkyl groups, wherein

[0317] R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and

[0318] R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups;

[0319] R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein

[0320] R 2 The C 1-6 The alkyl group is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and

[0321] R 2 The C3-10 Cycloalkyl is optionally substituted with one or more -OH;

[0322] If it exists, then R 3 It is C 1-6 alkyl;

[0323] L 1 It is C 1-6 Alkylene, where L 1 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 alkyl substituted, and wherein the C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution;

[0324] L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and

[0325] Choose one of the following:

[0326] (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein

[0327] The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution,

[0328] L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, and

[0329] The 3-10 membered heterocyclyl is optionally substituted with one or more -OH;

[0330] X 1 and X 2 are each independently N or C(R 5 );and

[0331] R 4 yes:

[0332] (i)-S(O) 2 -R a ;

[0333] (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6Alkyl substitution;

[0334] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0335] (iv)-NS(O)-(C 1-6 alkyl) 2 , wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0336] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 alkyl or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0337] (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a replace,

[0338] (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl),

[0339] (viii) -CN,

[0340] (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 6,

[0341] (x)-C(O)-C 1-6 Alkyl, or

[0342] (xi)-P(O)(C1-6 alkyl) 2 ;

[0343] or

[0344] (2)L 3 does not exist; and

[0345] X 1 and X 2 One of them is N or C (R 5 );and

[0346] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein

[0347] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Substitution, where R b is independently selected at each occurrence from halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0348] R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 is cycloalkyl substituted, and

[0349] Where R b The C 1-6 The C of the alkyl 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 alkyl or -OH substituted, and

[0350] R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 Alkyl substituted, and

[0351] Where R bThe C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH groups, and

[0352] The 5-20 membered heteroaryl group is optionally substituted by one or more R c Substitution, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0353] R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution,

[0354] R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution,

[0355] And R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substituted, and

[0356] Where R c The C of the 3-10 membered heterocyclic group 1-6 The alkyl group is further optionally substituted with one or more -OH groups;

[0357] R a independently at each occurrence is:

[0358] (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution,

[0359] (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, or

[0360] (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substitution;

[0361] R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups; and

[0362] R 6 and R 7 Each is independently H or halo.

[0363] Provided herein are compounds of formula (I):

[0364]

[0365] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

[0366] m is an integer from 0 to 4;

[0367] n is an integer from 0 to 2;

[0368] p is an integer from 0 to 10;

[0369] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy or -C 1-6 The group consisting of alkyl groups, wherein

[0370] R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and

[0371] R 1 The C 1-6The alkyl group is optionally substituted with one or more halo groups;

[0372] R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein

[0373] R 2 The C 1-6 The alkyl group is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and

[0374] R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH;

[0375] If it exists, then R 3 It is C 1-6 alkyl;

[0376] L 1 It is C 1-6 Alkylene, where L 1 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 alkyl substituted, and wherein the C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution;

[0377] L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and

[0378] Choose one of the following:

[0379] (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein

[0380] L 3 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 Alkyl substituted, and

[0381] The 3-10 membered heterocyclyl is optionally substituted with one or more -OH;

[0382] X 1 and X 2 are each independently N or C(R 5 );and

[0383] R 4 yes:

[0384] (i)-S(O) 2 -R a ,

[0385] (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution,

[0386] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0387] (iv)-NS(O)-(C 1-6 alkyl) 2 , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups,

[0388] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 alkyl or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0389] (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl or oxo substituted,

[0390] (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl), or

[0391] (viii) -CN;

[0392] or

[0393] (2)L 3 does not exist; and

[0394] X 1 and X 2 One of them is N or C (R 5 );and

[0395] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein

[0396] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Substitution, where R b is independently selected at each occurrence from halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0397] R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH or -S(O) 2 -C 1-6 Alkyl substituted, and

[0398] R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH groups, and

[0399] The 5-20 membered heteroaryl group is optionally substituted by one or more R c Substitution, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -Ra , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein

[0400] R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substituted, and

[0401] R c The C 3-10 Cycloalkyl is optionally substituted with one or more -OH;

[0402] R a independently at each occurrence is:

[0403] (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substituted, or

[0404] (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, or

[0405] (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substitution;

[0406] R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 The alkoxy group is optionally substituted with one or more halo groups; and

[0407] R 6 and R 7 Each is independently H or halo.

[0408] Any embodiment or any variation or embodiment of a compound of formula (I) or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing provided herein is also an embodiment or any variation or embodiment of a compound of formula (I') or formula (II) or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0409] In some embodiments of a compound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0 to 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some variations, the embodiments provided herein also apply to a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In some embodiments of a compound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein R 2 The C 1-6 The alkyl group is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. 2 It is H, C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein R 2 The C 1-3 The alkyl group is optionally substituted with one or more halo, -OH, -NH 2 or C 1-3 Alkoxy substituted, and R 2 The C 3-6 Cycloalkyl is optionally substituted with one or more -OH. 2 Choose from H, In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0410] In some embodiments of the compound of Formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein R 2 The C 1-6 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. 2 It is H, C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein R 2 The C 1-3 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-3 Alkoxy substituted, and R 2 The C 3-6 Cycloalkyl is optionally substituted with one or more -OH. 2 Choose from H, Composed of groups.

[0411] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0412] In some embodiments of the compound of Formula (I), Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 It is C 1-6 In some embodiments, R 2 It is C 1-3 In some embodiments, R 2 is methyl or ethyl. In some embodiments, R 2 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0413] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 Alkoxy substituted C 1-6 In some embodiments, R 2 is optionally substituted with one or more halo, -OH, -NH 2 or C 1-3 Alkoxy substituted C 1-3 In some embodiments, R 2 In some embodiments, R 2 is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 In some embodiments, R 2 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0414] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is optionally substituted with one or more deuterium, halide, -OH, -NH 2 or C 1-6 Alkoxy substituted C 1-6 In some embodiments, R 2 is optionally substituted with one or more deuterium, halide, -OH, -NH 2 or C 1-3 Alkoxy substituted C 1-3 In some embodiments, R 2 In some embodiments, R 2 is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 In some embodiments, R 2 Freedom to choose Composed of groups.

[0415] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 It is C 3-10 Cycloalkyl, where R 2 The C 3-10Cycloalkyl is optionally substituted with one or more -OH. 2 It is C 3-6 Cycloalkyl, where R 2 The C 3-6 Cycloalkyl is optionally substituted with one or more -OH. 2 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0416] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is a 3-15 membered heterocyclyl. 2 is a 3-6 membered heterocyclyl. 2 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0417] In some embodiments of a compound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some variations, the embodiments provided herein also apply to a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0418] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is a halogen, -CN, C 1-6 Alkoxy or -C 1-6 Alkyl, wherein the C 1-6 Alkoxy or R 1 is optionally substituted with one or more halo groups, and wherein R 1 The C 1-6 Alkyl is optionally substituted with one or more halo groups. 1 It is a halogen, -CN, C 1-3 Alkoxy or -C 1-3 Alkyl, where R 1The C 1-3 The alkoxy group is optionally substituted with one or more halo groups, and wherein R 1 The C 1-3 Alkyl is optionally substituted with one or more halo groups. 1 Selected from Cl, Br, -CN, methyl, In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0419] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is a halogen, -CN, C 1-6 Alkoxy or -C 1-6 Alkyl, wherein the C 1-6 Alkoxy or R 1 is optionally substituted with one or more halo groups, and wherein R 1 The C 1-6 Alkyl is optionally substituted with one or more halo groups. 1 It is a halogen, -CN, C 1-3 Alkoxy or -C 1-3 Alkyl, where R 1 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups, and wherein R 1 The C 1-3 Alkyl is optionally substituted with one or more halo groups. 1 Selected from Cl, Br, F, I, -CN, methyl, In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0420] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 In some embodiments, R 1 is Cl. In some embodiments, R 1 is Br. In some embodiments, R 1is F. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0421] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 In some embodiments, R 1 In some embodiments, R 1 is Br. In some embodiments, R 1 is F. In some embodiments, R 1 is I. In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0422] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is C 1-6 Alkyl, where R 1 The C 1-6 Alkyl is optionally substituted with one or more halo groups. 1 It is C 1-3 Alkyl, where R 1 The C 1-3 Alkyl is optionally substituted with one or more halo groups. 1 It is C 1-3 Alkyl, where R 1 The C 1-3 Alkyl is optionally substituted with one or more F. In some embodiments, R 1 is a methyl group, where R 1 The methyl group of is optionally substituted with one or more F. In some embodiments, R 1 In some embodiments, R 1 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0423] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0424] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is C 1-6 Alkoxy, where R 1 The C 1-6 Alkoxy is optionally substituted with one or more halo. 1 It is C 1-3 Alkoxy, where R 1 The C 1-3 Alkoxy is optionally substituted with one or more halo. 1 It is C 1-3 Alkoxy, where R 1 The C 1-3 Alkoxy is optionally substituted with one or more F. In some embodiments, R 1 is a methoxy group, where R 1 The methoxy group of is optionally substituted with one or more F. In some embodiments, R 1 yes In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0425] In some embodiments of a compound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, p is an integer from 0 to 10. In some embodiments, p is 0 or 1. In some embodiments, p is 0. In some embodiments, p is 1. In some variations, the embodiments provided herein also apply to a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0426] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 3 It is C 1-6 In some embodiments, R 3 It is C 1-3 In some embodiments, R 3is methyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0427] In some embodiments of the compound of formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, the compound with (R 1 ) m and R 2 The ring is a 2-indolinone optionally substituted at one or more of positions 1, 5, and 7. In some embodiments, the 2-indolinone ring is unsubstituted. In some embodiments, the 2-indolinone ring is substituted at position 1. In some embodiments, the 2-indolinone ring is substituted at position 5. In some embodiments, the 2-indolinone ring is substituted at position 7. In some embodiments, the 2-indolinone ring is substituted at positions 1 and 5. In some embodiments, the 2-indolinone ring is substituted at positions 5 and 7. In some embodiments, the 2-indolinone ring is substituted at positions 1, 5, and 7. In some embodiments, positions 1, 5, and 7 are as in the structure , wherein position 1 is an N atom, each of positions 5 and 7 is a C atom, and ## indicates the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, or any variations or embodiments thereof.

[0428] In some embodiments of the compound of formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, the compound with (R 1 ) m and R 2 Freedom of choice In some variations, the embodiments provided herein also apply to compounds of formula (I') or formula (II) or their stereoisomers or tautomers or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0429] In some embodiments of the compound of Formula (I), Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound having (R 1 ) m and R 2 Freedom of choice wherein ## represents the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0430] In some embodiments of the compound of formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, the compound with (R 1 ) m and R 2 Freedom of choice where ## indicates the point of attachment to the rest of the molecule.

[0431] In some embodiments of the compound of formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, the compound with (R 3 ) p Freedom of choice In some variations, the embodiments provided herein also apply to compounds of formula (I') or formula (II) or their stereoisomers or tautomers or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0432] In some embodiments of the compound of formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, the compound with (R 1 ) m , R 2 and (R 3 ) p Freedom of choice In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0433] In some embodiments of the compound of formula (I') or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, the compound with (R 1 ) m , R 2 and (R 3 ) p Freedom of choice In some embodiments, the group consisting of (R 1) m , R 2 and (R 3 ) p Freedom of choice In some embodiments, the group consisting of (R 1 ) m , R 2 and (R 3 ) p Freedom of choice In some embodiments, the group consisting of (R 1 ) m , R 2 and (R 3 ) p The ring is In some embodiments, the 1 ) m , R 2 and (R 3 ) p The ring is In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0434] In some embodiments of the compound of formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, the compound with (R 1 ) m , R 2 and (R 3 ) p Freedom of choice In some embodiments, the group consisting of (R 1 ) m , R 2 and (R 3 ) p Freedom of choice In some embodiments, the group consisting of (R 1 ) m , R 2 and (R 3 ) p Freedom of choice In some embodiments, the group consisting of (R 1 ) m , R 2 and (R 3 ) pThe ring is In some embodiments, the 1 ) m , R 2 and (R 3 ) p The ring is In some embodiments, the 1 ) m , R 2 and (R 3 ) p The ring is

[0435] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 is optionally replaced by one or more C 1-6 Alkyl substituted C 1-6 Alkylene, wherein the C 1-6 The alkyl group is optionally replaced by -OH or C 1-6 In some embodiments, L 1 is optionally replaced by one or more C 1-3 Alkyl substituted C 1-3 Alkylene, wherein the C 1-3 The alkyl group is optionally replaced by -OH or C 1-3 In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 is optionally replaced by one or more C 1-3 Alkyl-substituted ethylene, wherein the C 1-3 The alkyl group is optionally substituted with one or more -OH or C 1-3 In some embodiments, L 1 Freedom to choose The group of components, where for each L 1 , # indicates the same as L 2 The attachment point of and ## represents the attachment point to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0436] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 is optionally substituted with one or more deuterium or C 1-6 Alkyl substituted C 1-6Alkylene, wherein the C 1-6 The alkyl group is optionally replaced by -OH or C 1-6 In some embodiments, L 1 is optionally substituted with one or more deuterium or C 1-3 Alkyl substituted C 1-3 Alkylene, wherein the C 1-3 The alkyl group is optionally replaced by -OH or C 1-3 In some embodiments, L 1 In some embodiments, L 1 In some embodiments, L 1 is optionally substituted with one or more deuterium or C 1-3 Alkyl-substituted ethylene, wherein the C 1-3 The alkyl group is optionally substituted with one or more -OH or C 1-3 In some embodiments, L 1 Freedom to choose The group of components, where for each L 1 , # indicates the same as L 2 and ## indicates the point of attachment to the rest of the molecule.

[0437] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 2 is O or N (R x ), where R x Is H or C 1-6 In some embodiments, L 2 is O or N (R x ), where R x Is H or C 1-3 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0438] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 2 is O. In some variations, the embodiments provided herein also apply to a compound of formula (I') or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0439] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 Alkyl substitution, L 3 The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH groups, and L 3 The 3-10 membered heterocyclyl of is optionally substituted with one or more -OH. 3 Does not exist or is selected from O, In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0440] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein the C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution, L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L is substituted with an alkyl radical, and the 3-10 membered heterocyclyl radical is optionally substituted with one or more -OH radicals. 3 Does not exist or is selected from O, In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0441] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, where L 3 The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted; L3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH; and the 3-10 membered heterocyclyl group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 3 Does not exist or is selected from O, Composed of groups.

[0442] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 3 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0443] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is O. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0444] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 In some embodiments, L 3 It is C 1-3 In some embodiments, L 3 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0445] In some embodiments of the compound of Formula (I), Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C1-6 In some embodiments, L 3 It is C 1-3 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 3 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0446] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, wherein the C 1-6 Alkyl is optionally substituted with one or more -OH. 3 It is C 1-3 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 3 Freedom to choose Composed of groups.

[0447] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 3-10 Cycloalkyl, where L 3 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. 3 It is C 3-8 Cycloalkyl, where L 3 The C 3-8 Cycloalkyl is optionally substituted with one or more -OH. 3 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0448] In some embodiments of a compound of Formula (I'), Formula (I), Formula (IA), Formula (I-A2), Formula (IB), or Formula (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 3-10 Cycloalkyl, where L 3 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. 3 It is C 3-8 Cycloalkyl, where L 3 The C 3-8 Cycloalkyl is optionally substituted with one or more -OH. 3 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0449] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. 3 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0450] In some embodiments of the compound of formula (I), formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. In some embodiments, L3 is selected from In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0451] In some embodiments of the compound of formula (II) or its stereoisomer or tautomer or a pharmaceutically acceptable salt of any of the foregoing, L3 is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. In some embodiments, L3 is selected from Composed of groups.

[0452] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , 5-20 membered heteroaryl, -N(R d ) 2 、-NS(O)-(C 1-6 alkyl) 2 、-C(O)-N(R e ) 2 , 3-10 membered heterocyclic group, -S(O)(NC 1-6 Alkyl)-(C 1-6 In some embodiments, R 4 YesS(O) 2 -R a , 5-10 membered heteroaryl, -N(R d ) 2 、-NS(O)-(C 1-3 alkyl) 2 、-C(O)-N(R e ) 2 , 3-6 membered heterocyclic group, -S(O)(NC 1-3 Alkyl)-(C 1-3 In some embodiments, R 4 Select Free-NH 2 、-CN、-C(O)-N(CH 3 ) 2 , In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0453] In some embodiments of the compound of Formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a, 5-20 membered heteroaryl, -N(R d ) 2 、-NS(O)-(C 1-6 alkyl) 2 、-C(O)-N(R e ) 2 , 3-10 membered heterocyclic group, -S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl), -CN, -(CH 2 ) q OH, -C(O)-C 1-6 Alkyl or -P(O)(C 1-6 alkyl) 2 In some embodiments, R 4 YesS(O) 2 -R a , 5-10 membered heteroaryl, -N(R d ) 2 、-NS(O)-(C 1-3 alkyl) 2 、-C(O)-N(R e ) 2 , 3-6 membered heterocyclic group, -S(O)(NC 1-3 Alkyl)-(C 1-3 alkyl), -CN, -OH, -CH 2 OH, -C(O)-C 1-3 Alkyl or -P(O)(C 1-3 alkyl) 2 In some embodiments, R 4 Select Free-NH 2 、-CN、-OH、-CH 2 OH, -C(O)-N(CH 3 ) 2 , Composed of groups.

[0454] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a is optionally substituted with one or more halo, -OH, -S(O) 2 -C1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substituted C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-3 Alkyl or -N(C 1-3 alkyl)-C(O)-C 1-3 Alkyl substituted C 1-3 In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0455] In some embodiments of the compound of Formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substituted C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-3 Alkyl or -N(C 1-3 alkyl)-C(O)-C 1-3 Alkyl substituted C 1-3 In some embodiments, R 4 Freedom to choose Composed of groups.

[0456] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 3-10 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a is optionally substituted with one or more -OH, C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted C 3-10 Cycloalkyl, wherein the C 1-6 Alkyl is optionally substituted with one or more -OH. 4 Yes-S(O) 2 -R a , where R a is optionally substituted with one or more -OH, C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted C 3-6 Cycloalkyl, wherein the C 1-6 Alkyl is optionally substituted with one or more -OH. 4 Yes-S(O) 2 -R a , where R a is optionally substituted with one or more -OH, C(O) 2 -C 1-3 Alkyl, -C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-C(O)-C 3-6 Heterocyclic or C 1-3 Alkyl substituted C 3-6 Cycloalkyl, wherein the C 1-3Alkyl is optionally substituted with one or more -OH. 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0457] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a is a 3-10 membered heterocyclyl. 4 Yes-S(O) 2 -R a , where R a is optionally replaced by one or more C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a is optionally replaced by one or more C 1-6 In some embodiments, wherein R 4 Yes-S(O) 2 -R a , where R a is optionally replaced by one or more C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0458] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is a 5-20 membered heteroaryl. 4 is optionally replaced by one or more C 1-6 In some embodiments, R 4 is optionally replaced by one or more C 1-6 In some embodiments, R 4 is optionally replaced by one or more C1-3 In some embodiments, R 4 is a 5-6 membered heteroaryl group optionally substituted with one or more methyl groups. 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0459] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and wherein R a It is C 1-6 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-3 Alkyl or -S(O) 2 -R a , where R d The C 1-3 The alkyl group is optionally substituted with one or more -OH groups, and wherein R a It is C 1-3 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-3 The alkyl group is optionally substituted with one or more -OH groups, and wherein R a In some embodiments, R 4 Select Free-NH 2 , In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0460] In some embodiments of the compound of Formula (I), Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and wherein R a It is C 1-6 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-3 Alkyl or -S(O) 2 -R a , where R d The C 1-3 The alkyl group is optionally substituted with one or more -OH groups, and wherein R a It is C 1-3 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-3 The alkyl group is optionally substituted with one or more -OH groups, and wherein R a In some embodiments, R 4 Select Free-NH 2 , In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0461] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 Yes-C(O)-N(R e ) 2 , where each R e independently H or C 1-6 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where each R e independently H or C 1-3 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where each R e is independently H or methyl. In some embodiments, R 4 Yes -C(O)-NH 2 In some embodiments, R 4 It is -C(O)-NH(CH 3 In some embodiments, R 4 It is -C(O)-N(CH 3 ) 2 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0462] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where each R e is independently H or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups. 4 Yes-C(O)-N(R e ) 2 , where each R e is independently H or a 3-6 membered heterocyclic ring, wherein the 3-6 membered heterocyclic ring is optionally substituted with one or more oxo groups. 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0463] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the N to which they are attached, they form a 3-10 membered heterocyclic group. 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, -NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a It is C 1-6 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-7 membered heterocyclic group, wherein the 3-7 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a It is C 1-3 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-7 membered heterocyclic group, wherein the 3-7 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, -NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0464] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is optionally substituted with one or more oxo groups or C 1-6 In some embodiments, R 4 is optionally substituted with one or more oxo groups or C 1-6 In some embodiments, R 4 is optionally substituted with one or more oxo groups or C 1-3 In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0465] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is optionally replaced by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 is optionally replaced by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 is optionally replaced by one or more C 1-3 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0466] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is optionally replaced by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 is optionally replaced by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 is optionally replaced by one or more C 1-3 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0467] In some embodiments of the compound of Formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is optionally replaced by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 is optionally replaced by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 is optionally replaced by one or more C 1-3 Alkyl, -OH, oxo or -S(O) 2 R a In some embodiments, R 4 Freedom to choose Composed of groups.

[0468] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-NS(O)-(C 1-6alkyl) 2 In some embodiments, R 4 Yes-NS(O)-(C 1-3 alkyl) 2 In some embodiments, R 4 yes

[0469] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O)(NC 1-6 Alkyl)-(C 1-6 In some embodiments, R 4 Yes-S(O)(NC 1-3 Alkyl)-(C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0470] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0471] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-(CH 2 ) q OH, wherein q is an integer from 0 to 6. 4 Yes-(CH 2 ) q OH, wherein q is an integer from 0 to 2. In some embodiments, R 4 In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0472] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-C 1-6 In some embodiments, R 4 Yes-C(O)-C 1-3 In some embodiments, R 4 is -C(O)CH 3 In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0473] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-P(O)(C 1-6 alkyl) 2 In some embodiments, R 4 Yes-P(O)(C 1-3 alkyl) 2 In some embodiments, R 4 Yes -P(O)(CH 3 ) 2 In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0474] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 and X 2 Each of which is independently N or C(R 5 ). In some embodiments, X 1 and X 2 Each of is N. In some embodiments, X 1 and X 2 Each of them is C(R 5 ). In some embodiments, X 1 and X 2 One of them is CR 5 , and X 1 and X 2 The other of which is N. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0475] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 and X 2 One of them is CR 5 , and X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form a b In some embodiments, X 1 and X 2 One of them is CR 5 , and X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form a b Substituted 5-8 membered heterocyclyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0476] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b It is a halogen, an oxo, a C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 Cycloalkyl and 3-10 membered heterocyclic group, wherein R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH or -S(O) 2 -C 1-6 Alkyl substituted, and R b The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. b It is a halogen, an oxo, a C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, where R b The C 1-3 The alkyl group is optionally substituted with one or more halo, OH or -S(O) 2 -C 1-3 Alkyl substituted, and R b The C 3-6 Cycloalkyl is optionally substituted with one or more -OH. b Selected from oxo, -S(O) 2 CH 3 , In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0477] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b is independently selected at each occurrence from halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 Cycloalkyl substituted, where R b The C 1-6 The C of the alkyl 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 Alkyl or -OH substituted, and R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 Alkyl substituted, where Rb The C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH groups. b is independently selected at each occurrence from halo, oxo, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein R b The C 1-3 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-3 Alkyl or C 3-6 Cycloalkyl substituted, where R b The C 1-3 The C of the alkyl group 3-6 The cycloalkyl group is further optionally substituted with one or more C 1-3 Alkyl or -OH substituted, and R b The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C 1-3 Alkyl substituted, where R b The C 3-6 The C of the cycloalkyl group 1-3 The alkyl group is further optionally substituted with one or more -OH groups. b Selected from oxo, -S(O) 2 CH 3 , In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0478] In some embodiments of the compound of Formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b independently selected at each occurrence from -OH, halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 Cycloalkyl substituted, where R b The C 1-6 The C of the alkyl 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 Alkyl or -OH substituted, and R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 Alkyl substituted, where R b The C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide. b independently selected at each occurrence from -OH, halo, oxo, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein R b The C 1-3 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-3 Alkyl or C 3-6 Cycloalkyl substituted, where R b The C 1-3 The C of the alkyl 3-6 The cycloalkyl group is further optionally substituted with one or more C 1-3 Alkyl or -OH substituted, and R b The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C1-3 Alkyl substituted, where R b The C 3-6 The C of the cycloalkyl group 1-3 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide. b Selected from -OH, oxo, -S(O) 2 CH 3 , Composed of groups.

[0479] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b is oxo. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0480] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b It is C 1-6 In some embodiments, R b is optionally substituted with one or more halo, OH or -S(O) 2 -C 1-6 Alkyl substituted C 1-6 In some embodiments, R b is optionally substituted with one or more halo, OH or -S(O) 2 -C 1-3 Alkyl substituted C 1-3 In some embodiments, R b Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0481] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b It is C 1-6 In some embodiments, R b C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C1-6 Alkyl or C 3-10 Cycloalkyl substituted, where R b The C 1-6 The C of the alkyl 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 In some embodiments, R b is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-3 Alkyl or C 3-6 Cycloalkyl substituted C 1-3 Alkyl, where R b The C 1-3 The C of the alkyl 3-6 The cycloalkyl group is further optionally substituted with one or more C 1-3 In some embodiments, R b Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0482] In some embodiments of the compound of Formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b It is C 1-6 In some embodiments, R b C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 Cycloalkyl substituted, where R b The C 1-6 The C of the alkyl 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 In some embodiments, R b is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-3 Alkyl or C 3-6 Cycloalkyl substituted C 1-3 Alkyl, where R b The C 1-3 The C of the alkyl 3-6 The cycloalkyl group is further optionally substituted with one or more C 1-3 In some embodiments, R b Freedom to choose Composed of groups.

[0483] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b is -C(O)-NH(C 1-6 In some embodiments, R b is -C(O)-NH(C 1-3 In some embodiments, R b yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0484] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b Yes-C(O)-C 1-6 In some embodiments, R b Yes-C(O)-C 1-3 In some embodiments, R b yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0485] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R b Yes-S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R b Yes-S(O) 2 -R a , R a In some embodiments, R b Yes-S(O) 2 CH 3In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0486] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b is C optionally substituted with one or more -OH 3-10 In some embodiments, R b is C optionally substituted with one or more -OH 3-6 In some embodiments, R b yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0487] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 Alkyl substituted C 3-10 Cycloalkyl, wherein the C 1-6 The alkyl group is further optionally substituted with one or more -OH groups. b is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C 1-3 Alkyl substituted C 3-6 Cycloalkyl, wherein the C 1-3 The alkyl group is further optionally substituted with one or more -OH groups. b Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0488] In some embodiments of the compound of Formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 Alkyl substituted C 3-10 Cycloalkyl, wherein the C 1-6The alkyl group is further optionally substituted with one or more -OH, deuterium or halide. b is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C 1-3 Alkyl substituted C 3-6 Cycloalkyl, wherein the C 1-3 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide. b Freedom to choose Composed of groups.

[0489] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R b is a 3-10 membered heterocyclyl. b is a 3-6 membered heterocyclyl. b yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0490] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 and X 2 One of them is CR 5 , and X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form a 5-10 membered heteroaryl. 1 and X 2 One of them is CR 5 , and X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form a 5-6 membered heteroaryl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0491] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 and X 2 One of them is CR 5, and X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form a c In some embodiments, X 1 and X 2 One of them is CR 5 , and X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form a c Substituted 5-6 membered heteroaryl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0492] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R c Is a halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 Cycloalkyl and 3-10 membered heterocyclic groups, where R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substituted, and R c The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. c Is a halogen, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, where R c The C1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-3 Alkyl substituted, and R c The C 3-6 Cycloalkyl is optionally substituted with one or more -OH. c Selected from methyl, isopropyl, -S(O) 2 CH 3 and In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0493] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution, R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, and R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is further optionally substituted with one or more -OH groups. c independently selected at each occurrence from halogen, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -Ra , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein R c The C 1-3 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-3 Alkyl substitution, R c The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substituted, and R c The 3-6 membered heterocyclic group is optionally substituted by one or more -OH or C 1-3 Alkyl substituted, wherein the C 1-3 The alkyl group is further optionally substituted with one or more -OH groups. c Selected from methyl, isopropyl, -S(O) 2 CH 3 and In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0494] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R c It is C 1-6 Alkyl, -S(O) 2 -R a In some embodiments, R c It is C 1-3 In some embodiments, R c In some embodiments, R c is isopropyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0495] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R c is optionally replaced by one or more -S(O) 2 -R a Substituted C 1-6 Alkyl, where R a It is C 1-6 In some embodiments, R c is optionally replaced by one or more -S(O) 2 -Ra Substituted C 1-3 Alkyl, where R a It is C 1-3 In some embodiments, R c is optionally replaced by one or more -S(O) 2 -R a Substituted C 1-3 Alkyl, where R a is methyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0496] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R c is C optionally substituted with one or more -OH 3-10 In some embodiments, R c is C optionally substituted with one or more -OH 3-6 In some embodiments, R c yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0497] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R c is optionally replaced by one or more -OH or C 1-6 Alkyl substituted C 3-10 In some embodiments, R c is optionally replaced by one or more -OH or C 1-3 Alkyl substituted C 3-6 In some embodiments, R c Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0498] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R c is optionally replaced by one or more -OH or C 1-6alkyl-substituted 3-10 membered heterocyclic group, wherein the C 1-6 The alkyl group is further optionally substituted with one or more -OH groups. c is optionally replaced by one or more -OH or C 1-3 alkyl-substituted 3-6 membered heterocyclic group, wherein the C 1-3 The alkyl group is further optionally substituted with one or more -OH groups. c Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0499] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 Alkoxy is optionally substituted with one or more halo. 5 is independently H, halo, -CN, 3-6 membered heterocyclyl, C 1-3 Alkyl or C 1-3 Alkoxy, where R 5 The C 1-3 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-3 Alkoxy is optionally substituted with one or more halo. 5 Selected from H, Cl, F, -CN, In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0500] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0501] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 In some embodiments, R 5 is Cl or F. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0502] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0503] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 It is C 1-6 In some embodiments, R 5 It is C 1-3 In some embodiments, R 5 In some embodiments, R 5 It is C 1-6 Alkyl, where R 5 The C 1-6 Alkyl is optionally substituted with one or more halo or -OH. 5 It is C 1-3 Alkyl, where R 5 The C 1-3 Alkyl is optionally substituted with one or more halo or -OH. 5 It is C 1-3 Alkyl, where R 5 The C 1-3 Alkyl is optionally substituted with one or more fluorine or -OH. 5 Independently selected from methyl, In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0504] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is a 3-10 membered heterocyclyl. 5 is a 3-6 membered heterocyclyl. 5 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0505] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is C optionally substituted by one or more halogen groups 1-6 In some embodiments, R 5 is C optionally substituted by one or more halogen groups 1-3 In some embodiments, R 5 is C optionally substituted by one or more fluorine 1-3 In some embodiments, R 5 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0506] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 and R 7 Each is independently H or halo. In some embodiments, R 6 and R 7 are each independently H or fluoro. 6 and R 7 Each of is H. In some embodiments, R 6 and R 7 In some embodiments, each of R 6 and R 7 One of them is H, and R 6 and R 7The other of which is fluorine. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0507] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a disubstituted phenyl group, in which one group is in the opposite position to the phenyl group and L 2 In some embodiments, the disubstituted phenyl group is selected from In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0508] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a disubstituted phenyl group, in which one group is in the opposite position to the phenyl group and L 2 In some embodiments, the disubstituted phenyl group is selected from

[0509] In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0510] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7The rings are combined to form a disubstituted phenyl group, in which one group is in the opposite position to the phenyl group and L 2 In some embodiments, the disubstituted phenyl group is selected from In some embodiments of the compound of formula (I) or its stereoisomer or tautomer or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a trisubstituted phenyl group, in which the two groups are in the same position relative to the phenyl group and L 2 In some embodiments, the trisubstituted phenyl group is selected from the group consisting of In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0511] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a trisubstituted phenyl group, in which the two groups are in the same position relative to the phenyl group and L 2 In some embodiments, the trisubstituted phenyl group is selected from the group consisting of Composed of groups.

[0512] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a tetrasubstituted phenyl group, wherein the three groups are in the position relative to the phenyl group and L 2 In some embodiments, the tetrasubstituted phenyl group is selected from the group consisting of In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0513] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a disubstituted pyridine, in which one group is in the opposite direction to pyridine and L 2 In some embodiments, the disubstituted pyridine is selected from In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0514] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a trisubstituted pyridine, in which the two groups are in the same position relative to pyridine and L 2 In some embodiments, the trisubstituted pyridine is In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0515] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a trisubstituted pyridine, in which the two groups are in the same position relative to pyridine and L 2 In some embodiments, the trisubstituted pyridine is selected from In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0516] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a trisubstituted pyridine, in which the two groups are in the same position relative to pyridine and L 2 In some embodiments, the trisubstituted pyridine is selected from Composed of groups.

[0517] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a disubstituted pyrimidine, in which the two groups are in the position relative to the pyrimidine and L 2 In some embodiments, the disubstituted pyrimidine is selected from In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0518] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a disubstituted pyrimidine, in which the two groups are in the position relative to the pyrimidine and L 2 In some embodiments, the disubstituted pyrimidine is selected from In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0519] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a disubstituted pyrimidine, in which the two groups are in the position relative to the pyrimidine and L 2 In some embodiments, the disubstituted pyrimidine is selected from In some embodiments, the disubstituted pyrimidine is selected from In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0520] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings are combined to form a disubstituted pyrimidine, in which the two groups are in the position relative to the pyrimidine and L 2 In some embodiments, the disubstituted pyrimidine is selected from Composed of groups.

[0521] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0522] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0523] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0524] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0525] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0526] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0527] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from Composed of a group of heterocyclic rings.

[0528] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The ring together forms In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The ring together forms In some embodiments, L 1 , L 2 And with L 3 , R 4 , R6 and R 7 The ring together forms In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0529] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The ring together forms In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The ring together forms In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The ring together forms

[0530] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0531] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0532] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1, L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The ring together forms In some variations, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The ring together forms In some variations, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The ring together forms In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0533] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 and R 4 The rings together form a selection from In some variations, L 1 , L 2 And with L 3 and R 4 The ring together forms In some variations, L1 , L 2 And with L 3 and R 4 The ring together forms

[0534] In some embodiments of the compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 And with L 3 , R 4 , R 6 and R 7 The rings together form a selection from In some variations, the embodiments provided herein also apply to compounds of formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0535] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 and with R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 and with R 6 and R 7 The ring together forms In some embodiments, L1 , L 2 and with R 6 and R 7 The ring together forms

[0536] In some embodiments of the compound of Formula (II) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, L 1 , L 2 and with R 6 and R 7 The rings together form a selection from In some embodiments, L 1 , L 2 and with R 6 and R 7 The ring together forms In some embodiments, L 1 , L 2 and with R 6 and R 7 The ring together is

[0537] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1 or 2, and L 2 is -O-. In some embodiments, n is 2, and L 2 In some embodiments, n is 1, and L 2 is O. In some embodiments, n is 1 or 2, L 2 is -O-, and R 4 Yes-S(O) 2 -R a In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0538] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1, p is 0, L 2 is O, and X 1 and X 2 Each of them is C(R 5 ), where each R 5 are independently H, halogen, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-6 Alkoxy is optionally substituted with one or more halo groups. In some embodiments, n is 1, p is 0, L 2 is O, and X 1 and X 2 Each of them is C(R 5 ), where each R 5 are independently H. In some embodiments, n is 1, p is 0, L 2 is O, and X 1 and X 2 Each of them is C(R 5 ), one of which R 5 is H and the other R 5 is a halogen, -CN, a 3-10 membered heterocyclic group, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 Alkoxy is optionally substituted with one or more halo groups. In some embodiments, n is 1, p is 0, L 2 is O, and X 1 and X 2 Each of them is C(R 5 ), where each R 5 are independently halogen, -CN, 3-10 membered heterocyclic, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 The alkoxy group is optionally substituted with one or more halo groups. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0539] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1, p is 0, L 2 It's O, X 1 and X 2 One of them is N, and X 1 and X 2 The other one is C(R5 ), where R 5 is H, halogen, -CN, 3-10 membered heterocyclic group, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-6 Alkoxy is optionally substituted with one or more halo groups. In some embodiments, n is 1, p is 0, L 2 It's O, X 1 and X 2 One of them is N, and X 1 and X 2 The other one is C(R 5 ), where R 5 is H. In some embodiments, n is 1, p is 0, L 2 It's O, X 1 and X 2 One of them is N, and X 1 and X 2 The other one is C(R 5 ), where R 5 is a halogen, -CN, a 3-10 membered heterocyclic group, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0540] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, n is 1, L 2 is O, and X 1 and X 2 Each of is N. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0541] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1, p is 0, L2 It's O, X 1 and X 2 One of them is C(R 5 ), where R 5 It is H, X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form (i) a 5-10 membered heterocyclic group, wherein the 5-10 membered heterocyclic group is optionally substituted by one or more R b or (ii) 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted by one or more R c Replace, and R 6 and R 7 Each of is H. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0542] In some embodiments of the compound of Formula (I) or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, n is 1, L 2 It's O, X 1 and X 2 One of them is C(R 5 ), where R 5 is H, halogen, -CN, 3-10 membered heterocyclic group, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-6 The alkoxy group is optionally substituted by one or more halo groups, X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form (i) a 5-10 membered heterocyclic group, wherein the 5-10 membered heterocyclic group is optionally substituted by one or more R b or (ii) 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted by one or more R c Replace, and R 6 and R 7 Each of is H. In some embodiments, n is 1, L 2 It's O, X 1 and X 2 One of them is C(R 5 ), where R 5It is H, X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form (i) a 5-10 membered heterocyclic group, wherein the 5-10 membered heterocyclic group is optionally substituted by one or more R b or (ii) 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted by one or more R c Replace, and R 6 and R 7 Each of is H. In some embodiments, n is 1, L 2 It's O, X 1 and X 2 One of them is C(R 5 ), where R 5 is a halogen, -CN, a 3-10 membered heterocyclic group, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-6 The alkoxy group is optionally substituted by one or more halo groups, X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form (i) a 5-10 membered heterocyclic group, wherein the 5-10 membered heterocyclic group is optionally substituted by one or more R b or (ii) 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted by one or more R c Replace, and R 6 and R 7 Each of is H. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0543] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1, p is 0, L 2 It's O, X 1 and X 2 One of them is N, X 1 and X 2 The other one is C, and the C and R 4 and the atoms to which they are attached together form (i) a 5-10 membered heterocyclic group, wherein the 5-10 membered heterocyclic group is optionally substituted by one or more Rb or (ii) 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted by one or more R c Replace, and R 6 and R 7 Each of is H. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0544] In some embodiments of a compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing:

[0545] m is an integer from 0 to 2;

[0546] n is an integer from 1 to 2;

[0547] p is an integer from 0 to 2;

[0548] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-3 Alkoxy or C 1-3 The group consisting of alkyl groups, wherein

[0549] R 1 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups, and

[0550] R 1 The C 1-3 The alkyl group is optionally substituted with one or more halo groups;

[0551] R 2 It is H, C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-10 membered heterocyclic group, wherein

[0552] R 2 The C 1-3 The alkyl group is optionally substituted with one or more halo, -OH, -NH 2 or C 1-3 Alkoxy substituted, and

[0553] R 2 The C 3-6 Cycloalkyl is optionally substituted with one or more -OH;

[0554] If it exists, then R 3 It is C 1-3 alkyl;

[0555] L 1 It is C1-3 Alkylene, where L 1 The C 1-3 The alkylene group is optionally substituted with one or more C 1-3 alkyl substituted, and wherein the C 1-3 The alkyl group is further optionally substituted with one or more -OH or C 1-3 Alkoxy substitution;

[0556] L 2 is O or N (R x ), where R x Is H or C 1-3 Alkyl; and

[0557] Choose one of the following:

[0558] (1)L 3 Does not exist or is O, C 3-6 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein

[0559] The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substitution,

[0560] L 3 The C 1-3 The alkylene group is optionally substituted with one or more -OH or C 1-3 Alkyl substituted, and

[0561] The 3-10 membered heterocyclyl is optionally substituted with one or more -OH;

[0562] X 1 and X 2 are independently N or -C(R 5 );and

[0563] R 4 yes:

[0564] (i)-S(O) 2 -R a ;

[0565] (ii) a 5- to 10-membered heteroaryl group, wherein R 4 The 5-10 membered heteroaryl group is optionally substituted by one or more C 1-3 Alkyl substitution;

[0566] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-3 Alkyl or -S(O) 2 -Ra , where R d The C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0567] (iv)-NS(O)-(C 1-3 alkyl) 2 , wherein the C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0568] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-3 alkyl or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0569] (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-3 Alkyl, -OH, oxo or -S(O) 2 R a replace,

[0570] (vii)-S(O)-N(C 1-3 Alkyl)-(C 1-3 alkyl),

[0571] (viii) -CN,

[0572] (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 4,

[0573] (x)-C(O)-C 1-3 Alkyl, or

[0574] (xi)-P(O)(C 1-3 alkyl) 2 ;

[0575] or

[0576] (2)L 3 does not exist; and

[0577] X 1and X 2 One of them is N or C (R 5 );and

[0578] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein

[0579] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Substitution, where R b is independently selected at each occurrence from halo, oxo, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein

[0580] R b The C 1-3 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-3 Alkyl or C 3-6 Cycloalkyl substituted, and

[0581] Where R b The C 1-3 The C of the alkyl group 3-6 The cycloalkyl group is further optionally substituted with one or more C 1-3 alkyl or -OH substituted, and

[0582] R b The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C 1-3 Alkyl substituted, and

[0583] Where R b The C 3-6 The C of the cycloalkyl group 1-3 The alkyl group is further optionally substituted with one or more -OH groups, and

[0584] The 5-10 membered heteroaryl group is optionally substituted by one or more R c Substitution, where R cindependently selected at each occurrence from halogen, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein

[0585] R c The C 1-3 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution,

[0586] R c The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution,

[0587] And R c The 3-6 membered heterocyclic group is optionally substituted by one or more -OH or C 1-3 Alkyl substituted, and

[0588] Where R c The C of the 3-6 membered heterocyclic group 1-3 The alkyl group is further optionally substituted with one or more -OH groups;

[0589] R a independently at each occurrence is:

[0590] (i)C 1-3 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-3 Alkyl or -N(C 1-3 alkyl)-C(O)-C 1-3 Alkyl substitution,

[0591] (ii)C 3-6 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-3 Alkyl, -C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 or -C(O)-C 3-6 Heterocyclic or C 1-3 Alkyl substituted, wherein the C 1-3The alkyl group is optionally substituted with one or more -OH groups, or

[0592] (iii) a 3-6 membered heterocyclic group, which is optionally substituted by one or more C 1-3 Alkyl substitution;

[0593] R 5 is independently H, halo, -CN, 3-6 membered heterocyclyl, C 1-3 Alkyl or C 1-3 Alkoxy, where R 5 The C 1-3 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups; and

[0594] R 6 and R 7 Each is independently H or halo. In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0595] In some embodiments of a compound of Formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing:

[0596] m is an integer from 0 to 2;

[0597] n is an integer from 1 to 2;

[0598] p is an integer from 0 to 1;

[0599] If it exists, then R 1 independently selected at each occurrence from Cl, Br, F, I, -CN, C 1-3 Alkoxy or C 1-3 The group consisting of alkyl groups, wherein

[0600] R 1 The C 1-3 The alkoxy group is optionally substituted with one or more F, and

[0601] R 1 The C 1-3 Alkyl is optionally substituted with one or more F;

[0602] R 2 It is H, C 1-3 Alkyl, C 3-4 Cycloalkyl or 3-4 membered heterocyclic group, wherein

[0603] R 2The C 1-3 The alkyl group is optionally substituted with one or more of F, -OH, -NH 2 or -OCH 3 Replace, and

[0604] R 2 The C 3-4 Cycloalkyl is optionally substituted with one or more -OH;

[0605] If it exists, then R 3 It is C 1-3 alkyl;

[0606] L 1 It is C 1-3 Alkylene, where L 1 The C 13 The alkylene group is optionally substituted with one or more methyl groups, and wherein the methyl groups are further optionally substituted with one or more -OH or -OCH 3 replace;

[0607] L 2 is O; and

[0608] Choose one of the following:

[0609] (1)L 3 Does not exist or is O, C 3-4 Cycloalkyl, 3-7 membered heterocyclic group or C 1-4 Alkylene, wherein

[0610] The C 3-4 The cycloalkyl group is optionally substituted with one or more -OH or -CH 3 replace;

[0611] L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH, -CH 3 Replace, and

[0612] X 1 and X 2 are each independently N or C(R 5 );and

[0613] R 4 yes:

[0614] (i)-S(O) 2 -R a ;

[0615] (ii) a 5- to 6-membered heteroaryl group, wherein R 4 The 5-6 membered heteroaryl group is optionally replaced by one or more -CH 3 replace;

[0616] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-3 Alkyl or -S(O) 2 -R a , where R d The C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0617] (iv)-NS(O)-(CH 3 ) 2

[0618] (v)-C(O)-N(R e ) 2 , where R e is independently H, CH 3 or a 3-6 membered heterocyclic ring, wherein the 3-6 membered heterocyclic ring is optionally substituted by one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-7 membered heterocyclic group, wherein the 3-7 membered heterocyclic group is optionally substituted by one or more F, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0619] (vi) a 3-7 membered heterocyclic group, which is optionally substituted by one or more C 1-3 Alkyl, -OH, oxo or -S(O) 2 R a replace,

[0620] (vii)-S(O)-N(CH 3 )-(CH 3 ),

[0621] (viii) -CN,

[0622] (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 2, or

[0623] (x)-C(O)-CH 3 ,or

[0624] (xi)-P(O)(CH 3 ) 2 ;

[0625] or

[0626] (2)L 3 does not exist; and

[0627] X 1 and X 2 One of them is N or C (R 5 );and

[0628] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-8 membered heterocyclyl or a 5-6 membered heteroaryl, wherein

[0629] The 5-8 membered heterocyclic group is optionally substituted by one or more R b Substitution, where R b independently selected at each occurrence from oxo, C 1-3 Alkyl, -C(O)-CH 3 、-C(O)-NH 2 、-C(O)-NH(CH 3 )、-C(O)-N(CH 3 ) 2 、-S(O) 2 -R a , C 3-4 A group consisting of a cycloalkyl group and a 3-4 membered heterocyclic group, wherein

[0630] R b The C 1-3 The alkyl group is optionally substituted with one or more of F, OH, -S(O) 2 -CH 3 or C 3-4 is cycloalkyl substituted, and

[0631] Where R b The C 1-3 The C of the alkyl 3-4 The cycloalkyl group is further optionally substituted with one or more CH 3 or -OH, and

[0632] R b The C 3-4 The cycloalkyl group is optionally substituted with one or more -OH, C 3-4 Cycloalkyl or C 1-3 Alkyl substituted, and

[0633] Where R b The C 3-4 The C of the cycloalkyl group 1-3 The alkyl group is further optionally substituted with one or more -OH groups, and

[0634] The 5-6 membered heteroaryl group is optionally substituted by one or more R c Substitution, where R c Independently choose C at each occurrence 1-3 Alkyl, -S(O) 2 -R a , C 3-4 A group consisting of a cycloalkyl group and a 3-4 membered heterocyclic group, wherein

[0635] R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -CH 3 replace

[0636] R c The C 3-4 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substitution,

[0637] And R c The 3-4 membered heterocyclic group is optionally substituted by one or more -OH or methyl groups, and

[0638] Where R c The methyl group of the 3-4 membered heterocyclyl is further optionally substituted with one or more -OH;

[0639] R a independently at each occurrence is:

[0640] (i)C 1-3 Alkyl, which is optionally substituted with one or more F, -OH, -S(O) 2 -CH 3 or -N(CH 3 )-C(O)-CH 3 replace,

[0641] (ii)C 3-4 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -CH 3 、-C(O)-NH(CH 3 )、-C(O)-N(CH 3 ) 2 or -C(O)-C 3-4 heterocyclyl or methyl, wherein the methyl is optionally substituted with one or more -OH, or

[0642] (iii) a 3-4 membered heterocyclic group, which is optionally substituted by one or more methyl groups;

[0643] R 5is independently H, Cl, F, -CN, 3-4 membered heterocyclyl, C 1-3 Alkyl or C 1-3 Alkoxy, where R 5 The C 1-3 The alkyl group is optionally substituted with one or more F or -OH, and wherein R 5 The C 1-3 Alkoxy is optionally substituted with one or more F; and

[0644] R 6 and R 7 Each is independently H or F. In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0645] In some embodiments of the compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

[0646] m is an integer from 0 to 2;

[0647] n is an integer from 1 to 2;

[0648] p is an integer from 0 to 1;

[0649] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-3 Alkoxy and C 1-3 The group consisting of alkyl groups, wherein

[0650] R 1 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups, and

[0651] R 1 The C 1-3 The alkyl group is optionally substituted with one or more halo groups;

[0652] R 2 It is H, C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein

[0653] R 2 The C 1-6 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-3 Alkoxy substituted, and

[0654] R 2 The C 3-6Cycloalkyl is optionally substituted with one or more -OH;

[0655] If it exists, then R 3 It is C 1-3 alkyl;

[0656] L 1 It is C 1-3 Alkylene, wherein

[0657] L 1 The C 1-6 The alkylene group is optionally substituted with one or more deuterium or C 1-3 alkyl substituted, and wherein

[0658] The C 1-3 The alkyl group is further optionally substituted with one or more -OH or C 1-3 Alkoxy substitution;

[0659] L 2 is O; and

[0660] Choose one of the following:

[0661] (1)L 3 Does not exist or is O, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group or C 1-3 Alkylene, wherein

[0662] L 3 The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substitution,

[0663] L 3 The C 1-3 The alkylene group is optionally substituted with one or more -OH or C 1-3 Alkyl substituted, where

[0664] The C 1-3 The alkyl group is optionally substituted with one or more -OH groups, and

[0665] L 3 The 3-6 membered heterocyclic group is optionally substituted by one or more -OH or C 1-3 Alkyl substitution;

[0666] X 1 and X 2 are each independently N or C(R 5 );and

[0667] R 4 yes:

[0668] (i)-S(O) 2 -Ra ;

[0669] (ii) a 5- to 10-membered heteroaryl group, wherein R 4 The 5-10 membered heteroaryl group is optionally substituted by one or more C 1-3 Alkyl substitution;

[0670] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-3 Alkyl or -S(O) 2 -R a ,in

[0671] R d The C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0672] (iv)-NS(O)-(C 1-3 alkyl) 2 , wherein the C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0673] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-3 Alkyl or 3-6 membered heterocyclic ring, wherein

[0674] R e The 3-6 membered heterocyclic ring is optionally substituted by one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-6 membered heterocyclic group, wherein

[0675] The 3-6 membered heterocyclic group is optionally substituted with one or more halogen, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0676] (vi) a 3-6 membered heterocyclic group, which is optionally substituted by one or more C 1-3 Alkyl, -OH, oxo or -S(O) 2 R a replace,

[0677] (vii)-S(O)-N(C 1-3 Alkyl)-(C 1-3 alkyl),

[0678] (viii) -CN,

[0679] (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 3,

[0680] (x)-C(O)-C 1-3 Alkyl, or

[0681] (xi)-P(O)(C 1-3 alkyl) 2 ;

[0682] or

[0683] (2)L 3 does not exist; and

[0684] X 1 and X 2 One of them is N or C (R 5 );and

[0685] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-8 membered heterocyclyl or a 5-10 membered heteroaryl, wherein

[0686] The 5-8 membered heterocyclic group is optionally substituted by one or more R b Replace, where

[0687] R b independently selected at each occurrence from -OH, halo, oxo, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein

[0688] R b The C 1-3 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-3 Alkyl or C 3-6 is substituted with a cycloalkyl radical, and wherein

[0689] R b The C1-3 The C of the alkyl 3-6 The cycloalkyl group is further optionally substituted with one or more C 1-3 alkyl or -OH substituted, and

[0690] R b The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C 1-3 alkyl substituted, and wherein

[0691] R b The C 3-6 The C of the cycloalkyl group 1-3 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide, and

[0692] The 5-10 membered heteroaryl group is optionally substituted by one or more R c Replace, where

[0693] R c independently selected at each occurrence from halogen, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein

[0694] R c The C 1-3 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-3 Alkyl substitution,

[0695] R c The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substituted, and

[0696] R c The 3-6 membered heterocyclic group is optionally substituted by one or more -OH or C 1-3 alkyl substituted, and wherein

[0697] R c The C of the 3-6 membered heterocyclic group 1-3 The alkyl group is further optionally substituted with one or more -OH groups;

[0698] Ra independently at each occurrence is:

[0699] (i)C 1-3 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-3 Alkyl or -N(C 1-3 alkyl)-C(O)-C 1-3 Alkyl substitution,

[0700] (ii)C 3-6 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-3 Alkyl, -C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 or -C(O)-C 3-6 Heterocyclic or C 1-3 Alkyl substituted, where

[0701] The C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0702] (iii) a 3-6 membered heterocyclic group, which is optionally substituted by one or more C 1-3 Alkyl substituted, or

[0703] (iv)NH(C 1-3 alkyl);

[0704] R 5 is independently H, halo, -CN, 3-6 membered heterocyclyl, C 1-3 Alkyl or C 1-3 Alkoxy, where

[0705] R 5 The C 1-3 The alkyl group is optionally substituted with one or more halo groups or -OH, and

[0706] R 5 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups;

[0707] X 3 is N or C (R 6 );

[0708] X 4 is N or C (R 7 );

[0709] and

[0710] R 6and R 7 Each is independently H or halo.

[0711] In some embodiments of the compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

[0712] m is an integer from 0 to 2;

[0713] n is 1;

[0714] p is an integer 0;

[0715] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-3 Alkoxy and C 1-3 The group consisting of alkyl groups, wherein

[0716] R 1 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups, and

[0717] R 1 The C 1-3 The alkyl group is optionally substituted with one or more halo groups;

[0718] R 2 It is H, C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein

[0719] R 2 The C 1-6 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-3 Alkoxy substituted, and

[0720] R 2 The C 3-6 Cycloalkyl is optionally substituted with one or more -OH;

[0721] L 1 It is C 1-3 Alkylene, wherein

[0722] L 1 The C 1-6 The alkylene group is optionally substituted with one or more deuterium;

[0723] L 2 is O; and

[0724] Choose one of the following:

[0725] (1)L 3 Does not exist or is O, C3-6 Cycloalkyl, 3-6 membered heterocyclic group or C 1-3 Alkylene, wherein

[0726] L 3 The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substitution,

[0727] L 3 The C 1-3 The alkylene group is optionally substituted with one or more -OH or C 1-3 Alkyl substituted, where

[0728] The C 1-3 The alkyl group is optionally substituted with one or more -OH groups, and

[0729] L 3 The 3-6 membered heterocyclic group is optionally substituted by one or more -OH or C 1-3 Alkyl substitution;

[0730] X 1 and X 2 are each independently N or C(R 5 );and

[0731] R 4 yes:

[0732] (i)-S(O) 2 -R a ;

[0733] (ii) a 5- to 10-membered heteroaryl group, wherein R 4 The 5-10 membered heteroaryl group is optionally substituted by one or more C 1-3 Alkyl substitution;

[0734] (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-3 Alkyl or -S(O) 2 -R a ,in

[0735] R d The C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0736] (iv)-NS(O)-(C 1-3 alkyl) 2 , wherein the C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0737] (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-3 Alkyl or 3-6 membered heterocyclic ring, wherein

[0738] R e The 3-6 membered heterocyclic ring is optionally substituted by one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-6 membered heterocyclic group, wherein

[0739] The 3-6 membered heterocyclic group is optionally substituted with one or more halogen, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace,

[0740] (vi) a 3-6 membered heterocyclic group, which is optionally substituted by one or more C 1-3 Alkyl, -OH, oxo or -S(O) 2 R a replace,

[0741] (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 3;

[0742] or

[0743] (2)L 3 does not exist; and

[0744] X 1 and X 2 One of them is N or C (R 5 );and

[0745] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-8 membered heterocyclyl or a 5-10 membered heteroaryl, wherein

[0746] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Replace, where

[0747] R b independently selected at each occurrence from -OH, halo, oxo, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein

[0748] R b The C 1-3 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-3 Alkyl or C 3-6 is substituted with a cycloalkyl radical, and wherein

[0749] R b The C 1-3 The C of the alkyl group 3-6 The cycloalkyl group is further optionally substituted with one or more C 1-3 alkyl or -OH substituted, and

[0750] R b The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C 1-3 alkyl substituted, and wherein

[0751] R b The C 3-6 The C of the cycloalkyl group 1-3 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide, and

[0752] The 5-10 membered heteroaryl group is optionally substituted by one or more R c Replace, where

[0753] R c independently selected at each occurrence from halogen, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein

[0754] R c The C 1-3 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-3Alkyl substitution,

[0755] R c The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substituted, and

[0756] R c The 3-6 membered heterocyclic group is optionally substituted by one or more -OH or C 1-3 alkyl substituted, and wherein

[0757] R c The C of the 3-6 membered heterocyclic group 1-3 The alkyl group is further optionally substituted with one or more -OH groups;

[0758] R a independently at each occurrence is:

[0759] (i)C 1-3 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-3 Alkyl or -N(C 1-3 alkyl)-C(O)-C 1-3 Alkyl substitution,

[0760] (ii)C 3-6 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-3 Alkyl, -C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 or -C(O)-C 3-6 Heterocyclic or C 1-3 Alkyl substituted, where

[0761] The C 1-3 The alkyl group is optionally substituted with one or more -OH groups,

[0762] (iii) a 3-6 membered heterocyclic group, which is optionally substituted by one or more C 1-3 Alkyl substituted, or

[0763] (iv)NH(C 1-3 alkyl);

[0764] R 5 is independently H, halo, -CN, 3-6 membered heterocyclyl, C 1-3 Alkyl or C 1-3 Alkoxy, where

[0765] R 5The C 1-3 The alkyl group is optionally substituted with one or more halo groups or -OH, and

[0766] R 5 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups;

[0767] X 3 is N or C (R 6 );

[0768] X 4 is N or C (R 7 );

[0769] and

[0770] R 6 and R 7 Each is independently H or halo.

[0771] In some embodiments of the compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

[0772] m is an integer from 0 to 2;

[0773] n is 1;

[0774] p is an integer 0;

[0775] If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-3 Alkoxy and C 1-3 The group consisting of alkyl groups, wherein

[0776] R 1 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups, and

[0777] R 1 The C 1-3 The alkyl group is optionally substituted with one or more halo groups;

[0778] R 2 It is H;

[0779] L 1 It is C 1-3 Alkylene, wherein

[0780] L 1 The C 1-6 The alkylene group is optionally substituted with one or more deuterium;

[0781] L 2 is O; and

[0782] Choose one of the following:

[0783] (1)L 3 Does not exist or C 1-3 Alkylene, wherein

[0784] L 3 The C 1-3 The alkylene group is optionally substituted with one or more -OH or C 1-3 Alkyl substitution;

[0785] X 1 and X 2 are each independently N or C(R 5 );and

[0786] R 4 yes:

[0787] (i)-S(O) 2 -R a ;

[0788] (ii)-(CH 2 ) q OH, wherein q is an integer from 0 to 3;

[0789] or

[0790] (2)L 3 does not exist; and

[0791] X 1 and X 2 One of them is N or C (R 5 );and

[0792] X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-8 membered heterocyclyl or a 5-20 membered heteroaryl, wherein

[0793] The 5-10 membered heterocyclic group is optionally substituted by one or more R b Replace, where

[0794] R b is independently oxo or C 3-6 Cycloalkyl, wherein the C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C 1-3 Alkyl substituted, and

[0795] The 5-10 membered heteroaryl group is optionally substituted by one or more R c Replace, where

[0796] R c Independently choose C at each occurrence 1-3 Alkyl, C 3-6 A group consisting of cycloalkyl groups, wherein R c The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substitution;

[0797] R a independently at each occurrence is:

[0798] (i)C 1-3 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-3 Alkyl or -N(C 1-3 alkyl)-C(O)-C 1-3 Alkyl substitution;

[0799] R 5 is independently H, halo, C 1-3 Alkyl or C 1-3 Alkoxy, where

[0800] R 5 The C 1-3 The alkyl group is optionally substituted with one or more halo groups or -OH, and

[0801] R 5 The C 1-3 The alkoxy group is optionally substituted with one or more halo groups;

[0802] X 3 is N or C (R 6 );

[0803] X 4 is N or C (R 7 );

[0804] and

[0805] R 6 and R 7 Each is independently H or halo.

[0806] In some embodiments, provided herein is a compound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of formula (IA):

[0807]

[0808] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: n is 1 or 2; and m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , X 1 , X 2 , R 6 and R 7 As defined for formula (I). In some variations, m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , X 1 , X 2 , R 6 and R 7 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0809] In some embodiments, provided herein is a compound of Formula (I) or Formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of Formula (I-A1):

[0810]

[0811] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , X 1 , X 2 , R 6 and R 7 As defined for formula (I). In some variations, m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , X 1 , X 2 , R 6 and R 7As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0812] In some embodiments of a compound of Formula (I), Formula (IA), or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0813] In some embodiments of a compound of Formula (I), Formula (IA) or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 0. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0814] In some embodiments of a compound of Formula (I), Formula (IA) or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, p is an integer from 0 to 10. In some embodiments, p is 0 or 1. In some embodiments, p is 0. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0815] In some embodiments of a compound of Formula (I), Formula (IA), or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 It is C 1-6 In some embodiments, L 1 It is C 1-3 In some embodiments, L 1 In some embodiments, L 1 yes wherein # represents the point of attachment to -O- and ## represents the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0816] In some embodiments of a compound of Formula (I), Formula (IA), or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0817] In some embodiments of a compound of Formula (I), Formula (IA), or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0818] In some embodiments of a compound of Formula (I), Formula (IA), or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 and X 2 Each of them is C(R 5 ). In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0819] In some embodiments of a compound of Formula (I), Formula (IA), or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0820] In some embodiments of a compound of Formula (I), Formula (IA), or Formula (I-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 and R 7 Each of is H. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0821] In some embodiments, provided herein is a compound of Formula (I) or Formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of Formula (I-A2):

[0822]

[0823] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , X 1 , X 2 , R 6 and R 7 As defined for formula (I). In some variations, m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , X 1 , X 2 , R 6 and R 7 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0824] In some embodiments, provided herein is a compound of Formula (I) or Formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of Formula (I-A3):

[0825]

[0826] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: n is 1 or 2; and wherein m, n, p, R 1 , R 2 , R 3 , L 1 , X 1 , X 2 , R 6 , R 7 and R a As defined for formula (I). In some variations, m, n, p, R 1 , R 2 , R 3 , L 1 , X 1 , X 2 , R 6 , R 7 and R a As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0827] In some embodiments, provided herein is a compound of Formula (I), Formula (IA), or Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (IB):

[0828]

[0829] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , R 5 , R 6 and R 7 As defined for formula (I). In some variations, m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 , R 5 , R 6 and R 7As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0830] In some embodiments, provided herein is a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-B1):

[0831]

[0832] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m, R 1 , R 2 , L 1 , L 3 , R 4 , R 6 and R 7 As defined for formula (I). In some variations, m, R 1 , R 2 , L 1 , L 3 , R 4 , R 6 and R 7 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0833] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0834] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 It is C 1-6 In some embodiments, R 2 It is C 1-3 In some embodiments, R 2is methyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0835] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is optionally substituted with one or more halogen, -OH or C 1-6 Alkoxy substituted C 1-6 In some embodiments, R 2 is optionally substituted with one or more halogen, -OH or C 1-3 Alkoxy substituted C 1-3 In some embodiments, R 2 is optionally substituted with one or more halogen, -OH, NH 2 or C 1-3 In some embodiments, R 2 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0836] In some embodiments of a compound of Formula (II) (such as a compound of Formula (IA), Formula (I-A2), Formula (IB), or Formula (I-B1)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is optionally substituted with one or more deuterium, halide, -OH or C 1-6 Alkoxy substituted C 1-6 In some embodiments, R 2 is optionally substituted with one or more deuterium, halide, -OH or C 1-3 Alkoxy substituted C 1-3 In some embodiments, R 2 is optionally substituted with one or more deuterium, halogen, -OH, NH 2 or C 1-3 In some embodiments, R 2 is optionally substituted with one or more deuterium, halogen, -OH, NH 2 or C 1-3 In some embodiments, R 2 Freedom to choose Composed of groups.

[0837] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is C optionally substituted with one or more -OH 3-10 In some embodiments, R 2 is C optionally substituted with one or more -OH 3-6 In some embodiments, R 2 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0838] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is a 3-15 membered heterocyclyl. 2 is a 3-6 membered heterocyclyl. 2 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0839] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0840] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 In some embodiments, R 1In some embodiments, R 1 is Br. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0841] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is C 1-6 In some embodiments, R 1 is methyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0842] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2), Formula (IB), or Formula (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is C 1-6 Alkyl, where R 1 The C 1-6 Alkyl is optionally substituted with one or more halo groups. 1 It is C 1-3 Alkyl, where R 1 The C 1-3 Alkyl is optionally substituted with one or more halo groups. 1 is a methyl group, where R 1 The methyl group of is optionally substituted with one or more F. In some embodiments, R 1 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0843] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0844] In some embodiments of a compound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, p is an integer from 0 to 10. In some embodiments, p is 0. In some variations, the embodiments provided herein also apply to a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0845] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 It is C 1-6 Alkylene, where L 1 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 In some embodiments, L 1 is optionally replaced by one or more C 1-3 Alkyl substituted C 1-3 In some embodiments, L 1 is optionally replaced by one or more C 1-6 In some embodiments, L 1 Freedom to choose The group of components, where for each L 1 , # represents the point of attachment to -O- and ## represents the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or their stereoisomers or tautomers or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0846] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0847] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C1-6 In some embodiments, L 3 It is C 1-3 In some embodiments, L 3 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0848] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 3-10 Cycloalkyl, where L 3 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. 3 It is C 3-8 Cycloalkyl, where L 3 The C 3-8 Cycloalkyl is optionally substituted with one or more -OH. 3 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0849] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. 3 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0850] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I), Formula (IA), Formula (I-A2), Formula (IB), or Formula (I-B1)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. 3 Freedom to choose Composed of groups.

[0851] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 Alkyl, where R a The C 1-6 The alkyl group is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-3 Alkyl, where R a The C 1-3 The alkyl group is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-3 Alkyl or -N(C 1-3 alkyl)-C(O)-C 1-3 In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0852] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I), Formula (IA), Formula (I-A2), Formula (IB), or Formula (I-B1)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Freedom to choose Composed of groups.

[0853] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 3-10 Cycloalkyl. 4 Yes-S(O) 2 -R a , where R a It is C 3-10 Cycloalkyl, where R a The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 Alkyl is optionally substituted with one or more -OH. 4 Yes-S(O) 2 -R a , where R a It is C 3-6 Cycloalkyl, where R a The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 Alkyl is optionally substituted with one or more -OH. 4 Yes-S(O) 2 -R a , where R a It is C 3-6 Cycloalkyl, where R a The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C(O) 2 -C1-3 Alkyl, -C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-C(O)-C 3-6 Heterocyclic or C 1-3 Alkyl substituted, wherein the C 1-3 Alkyl is optionally substituted with one or more -OH. 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0854] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a is a 3-10 membered heterocyclyl. 4 Yes-S(O) 2 -R a , where R a is a 3-10 membered heterocyclic group, wherein R a The 3-10 membered heterocyclic group is optionally substituted by one or more C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a is a 3-6 membered heterocyclic group, wherein R a The 3-6 membered heterocyclic group is optionally substituted by one or more C 1-6 In some embodiments, wherein R 4 Yes-S(O) 2 -R a , where R a is a 3-6 membered heterocyclic group, wherein R a The 3-6 membered heterocyclic group is optionally substituted by one or more C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0855] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is a 5-20 membered heteroaryl. 4 is optionally replaced by one or more C 1-6 In some embodiments, R 4 is optionally replaced by one or more C 1-6 In some embodiments, R 4 is optionally replaced by one or more C 1-3 In some embodiments, R 4 is a 5-6 membered heteroaryl group optionally substituted with one or more methyl groups. 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0856] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-N(R d ) 2 , where each R d independently H or C 1-6 Alkyl, where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH or -S(O) 2 -R a Substitution, where R a It is C 1-6 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d independently H or C 1-3 Alkyl, where R d The C 1-3 The alkyl group is optionally substituted with one or more -OH or -S(O) 2 -R a substituted, and wherein R a It is C 1-3In some embodiments, R 4 Yes-N(R d ) 2 , where each R d independently H or C 1-3 Alkyl, where R d The C 1-3 The alkyl group is optionally substituted with one or more -OH or -S(O) 2 -R a Substitution, where R a In some embodiments, R 4 Select Free-NH 2 , In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0857] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where each R e independently H or C 1-6 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where each R e independently H or C 1-3 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where each R e is independently H or methyl. In some embodiments, R 4 Yes -C(O)-NH 2 In some embodiments, R 4 It is -C(O)-NH(CH 3 In some embodiments, R 4 It is -C(O)-N(CH 3 ) 2 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0858] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the N to which they are attached, they form a 3-10 membered heterocyclic group. 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a It is C 1-6 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-7 membered heterocyclic group, wherein the 3-7 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a It is C 1-3 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-7 membered heterocyclic group, wherein the 3-7 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0859] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is a 3-10 membered heterocyclyl optionally substituted with one or more oxo groups. 4 is a 3-7 membered heterocyclyl optionally substituted with one or more oxo groups. 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0860] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-NS(O)-(C 1-6 alkyl) 2 In some embodiments, R 4 Yes-NS(O)-(C 1-3 alkyl) 2 In some embodiments, wherein R 4 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0861] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O)(NC 1-6 Alkyl)-(C 1-6 In some embodiments, R 4 Yes-S(O)-N(C 1-3 Alkyl)-(C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0862] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0863] In some embodiments of the compound of Formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-P(O)(C 1-6 alkyl) 2 In some embodiments, R 4 Yes-P(O)(C 1-3 alkyl) 2 In some embodiments, R 4 Yes -P(O)(CH 3 ) 2 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0864] In some embodiments, provided herein is a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-B2):

[0865]

[0866] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R 5 is a halogen, -CN, a 3-10 membered heterocyclic group, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 Alkoxy is optionally substituted with one or more halo groups; and m, R 1 , R 2 , L1 , L 3 , R 4 , R 6 and R 7 As defined for formula (I). In some variations, m, R 1 , R 2 , L 1 , L 3 , R 4 , R 6 and R 7 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0867] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0868] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 It is C 1-6 Alkyl, where R 2 The C 1-6 Alkyl is optionally substituted with one or more halo, -OH. 2 It is C 1-3 Alkyl, where R 2 The C 1-3 Alkyl is optionally substituted with one or more halo, -OH. 2 In some embodiments, R 2 is ethyl, where R 2 The ethyl group is optionally substituted with one or more halo groups, -OH groups. 2 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0869] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I), Formula (IA), Formula (I-A2), Formula (IB), or Formula (I-B2)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 It is C 1-6 Alkyl, where R 2 The C 1-6 Alkyl is optionally substituted with one or more deuterium. 2 It is C 1-3 Alkyl, where R 2 The C 1-3 Alkyl is optionally substituted with one or more deuterium. 2 is a methyl group, where R 2 The methyl group of is optionally substituted with one or more deuterium. 2 yes

[0870] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0871] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 In some embodiments, R 1 is Cl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0872] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0873] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 is optionally replaced by one or more C 1-6 Alkyl substituted C 1-6 Alkylene, wherein the C 1-6 The alkyl group is optionally replaced by -OH or C 1-6 In some embodiments, L 1 In some embodiments, L 1 is optionally replaced by one or more C 1-6 Alkyl-substituted ethylene, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 1 Freedom to choose The group of components, where for each L 1 , # represents the point of attachment to -O- and ## represents the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or their stereoisomers or tautomers or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0874] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0875] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. 3 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0876] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0877] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I), Formula (IA), Formula (I-A2), Formula (IB), or Formula (I-B2)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-NS(O)-(C 1-6 alkyl) 2 In some embodiments, R 4 Yes-NS(O)-(C 1-6 alkyl) 2 In some embodiments, R 4 Yes-NS(O)-(C 1-3 alkyl) 2 In some embodiments, R 4 yes

[0878] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-6 Alkyl or -S(O) 2 -Ra , where R a It is C 1-6 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-3 Alkyl or -S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d Independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R a In some embodiments, R 4 Select Free-NH 2 and In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0879] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where each R e independently H or C 1-6 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where each R e independently H or C 1-3 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where each R e is independently H or methyl. In some embodiments, R 4 Yes -C(O)-NH 2 In some embodiments, R 4 It is -C(O)-NH(CH 3 In some embodiments, R4 It is -C(O)-N(CH 3 ) 2 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0880] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where each R e is independently H or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups. 4 Yes-C(O)-N(R e ) 2 , where each R e is independently H or a 3-6 membered heterocyclic ring, wherein the 3-6 membered heterocyclic ring is optionally substituted with one or more oxo groups. 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0881] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the N to which they are attached, they form a 3-10 membered heterocyclic group. 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more oxo groups, -OH, NH 2 or -S(O) 2 -R a Substitution, where R a It is C 1-6 In some embodiments, R4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-7 membered heterocyclic group, wherein the 3-7 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a It is C 1-3 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the nitrogen to which they are attached, they form a 3-7 membered heterocyclic group, wherein the 3-7 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0882] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 In some embodiments, R 5 is Cl or F. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0883] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0884] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 It is C 1-6 Alkyl, where R 5 The C 1-6 Alkyl is optionally substituted with one or more halo or -OH. 5 It is C 1-3 Alkyl, where R 5 The C 1-3 Alkyl is optionally substituted with one or more halo or -OH. 5 It is C 1-3 Alkyl, where R 5 The C 1-3 Alkyl is optionally substituted with one or more fluorine or -OH. 5 Selected from methyl, In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0885] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is a 3-10 membered heterocyclyl. 5 is a 3-6 membered heterocyclyl. 5 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0886] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 It is C 1-6Alkoxy, wherein the C 1-6 Alkoxy is optionally substituted with one or more halo. 5 It is C 1-3 Alkoxy, wherein the C 1-3 Alkoxy is optionally substituted with one or more halo. 5 It is C 1-3 Alkoxy, wherein the C 1-3 Alkoxy is optionally substituted with one or more fluorine. 5 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0887] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 and R 7 Each is independently H or halo. In some embodiments, R 6 and R 7 are each independently H or fluoro. 6 and R 7 Each of is H. In some embodiments, R 6 and R 7 One of them is H and R 6 and R 7 The other of which is fluorine. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0888] In some embodiments, provided herein is a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-B3):

[0889]

[0890] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: each R 5 is independently at each occurrence halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 Alkoxy is optionally substituted with one or more halo groups; and m, R 1 , R 2 , L 1 , L 3 , R 4 , R 6 and R 7 As defined for formula (I). In some variations, m, R 1 , R 2 , L 1 , L 3 , R 4 , R 6 and R 7 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0891] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0892] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 It is C 1-6 In some embodiments, R 2 is methyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0893] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is 0 or 1. In some embodiments, m is 0. In some embodiments, m is 1. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0894] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 In some embodiments, R 1 is Cl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0895] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0896] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 is optionally replaced by one or more C 1-6 Alkyl substituted C 1-6 Alkylene, wherein the C 1-6 The alkyl group is optionally replaced by -OH or C 1-6 In some embodiments, L 1 In some embodiments, L 1 is optionally replaced by one or more C 1-6 Alkyl-substituted ethylene, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 1 Freedom to choose The group of components, where for each L 1 , # represents the point of attachment to -O- and ## represents the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or their stereoisomers or tautomers or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0897] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0898] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 In some embodiments, L 3 It is C 1-3 In some embodiments, L 3 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0899] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. 3 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0900] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0901] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-N(R d ) 2 , where each R d Independently C 1-6 Alkyl or -S(O) 2 -R a , and where R a It is C 1-6 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d Independently C 1-3 Alkyl or -S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R 4 Yes-N(R d ) 2 , where each R d is methyl or -S(O) 2 -R a , where Ra In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0902] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the N to which they are attached, they form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more oxo groups. 4 Yes-C(O)-N(R e ) 2 , where two R e Together with the N to which they are attached, they form a 3-7 membered heterocyclic group, wherein the 3-7 membered heterocyclic group is optionally substituted with one or more oxo groups. 4 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0903] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IB), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 is independently selected at each occurrence from the group consisting of halogen and C 1-6 In some embodiments, R 5 is independently selected at each occurrence from the group consisting of halogen and C 1-3 In some embodiments, R 5 is independently selected at each occurrence from the group consisting of F and methyl. 5 is F. In some embodiments, each R 5 is methyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0904] In some embodiments, provided herein is a compound of Formula (I), Formula (IA), or Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (IC):

[0905]

[0906] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 and R 5 As defined for formula (I). In some variations, m, p, R 1 , R 2 , R 3 , L 1 , L 3 , R 4 and R 5 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0907] In some embodiments, provided herein is a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (IC), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-C1):

[0908]

[0909] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m, R 1 , R 2 , R 3 , L 1 , L 3 and R 4 As defined for formula (I). In some variations, m, R 1 , R 2 , R 3 , L 1 , L 3 and R 4 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0910] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0911] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 1. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0912] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 In some embodiments, R 1 is Cl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0913] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0914] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 It is C 1-6 In some embodiments, L 1 In some embodiments, L 1 yes wherein # represents the point of attachment to -O- and ## represents the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0915] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0916] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 In some embodiments, L 3 It is C 1-3 In some embodiments, L 3 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0917] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0918] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 3-10 Cycloalkyl. 4 Yes-S(O) 2 -R a , where R a It is C 3-10 Cycloalkyl, where R a The C 3-10 The cycloalkyl group is optionally substituted with one or more C 1-6 alkyl substituted, and wherein the C 1-6 Alkyl is optionally substituted with one or more -OH. 4 Yes-S(O) 2 -R a , where R a It is C 3-6 Cycloalkyl, where R a The C 3-6 The cycloalkyl group is optionally substituted with one or more C 1-6 alkyl substituted, and wherein the C 1-6 Alkyl is optionally substituted with one or more -OH. 4 Yes-S(O) 2 -R a , where R a It is C 3-6 Cycloalkyl, where R a The C 3-6 The cycloalkyl group is optionally substituted with one or more C 1-3 Alkyl substituted, wherein the C 1-3 Alkyl is optionally substituted with one or more -OH. 4 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0919] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a is a 3-10 membered heterocyclyl. 4 Yes-S(O) 2 -R a , where R a is a 3-10 membered heterocyclic group, wherein R a The 3-10 membered heterocyclic group is optionally substituted by one or more C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a is a 3-6 membered heterocyclic group, wherein R a The 3-6 membered heterocyclic group is optionally substituted by one or more C 1-6 In some embodiments, wherein R 4 Yes-S(O) 2 -R a , where R a is a 3-6 membered heterocyclic group, wherein R a The 3-6 membered heterocyclic group is optionally substituted by one or more C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0920] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where each R e independently H or C 1-6 In some embodiments, R 4 Yes-C(O)-N(R e ) 2 , where each R e independently H or C 1-3 In some embodiments, R 4Yes-C(O)-N(R e ) 2 , where each R e is independently H or methyl. In some embodiments, R 4 Yes -C(O)-NH 2 In some embodiments, R 4 It is -C(O)-N(CH 3 ) 2 In some embodiments, R 4 Yes -C(O)-NH 2 In some embodiments, R 4 It is -C(O)-NH(CH 3 ). In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0921] In some embodiments, provided herein is a compound of Formula (I), Formula (IA), or Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-C2):

[0922]

[0923] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R 5 is a halogen, -CN, a 3-10 membered heterocyclic group, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 Alkoxy is optionally substituted with one or more halo groups; m, p, R 1 , R 2 , R 3 , L 1 , L 3 and R 4 As defined for formula (I). In some variations, R 5 is a halogen, -CN, a 3-10 membered heterocyclic group, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-6The alkoxy group is optionally substituted by one or more halogen groups; m, p, R 1 , R 2 , R 3 , L 1 , L 3 and R 4 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0924] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0925] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 1. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0926] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 In some embodiments, R 1 is Cl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0927] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0928] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2), Formula (IC), or Formula (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is C 1-6 Alkyl, where R 1 The C 1-6 Alkyl is optionally substituted with one or more halo groups. 1 It is C 1-3 Alkyl, where R 1 The C 1-3 Alkyl is optionally substituted with one or more halo groups. 1 is a methyl group, where R 1 The methyl group of is optionally substituted with one or more F. In some embodiments, R 1 yes In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0929] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 It is C 1-6 In some embodiments, L 1 In some embodiments, L 1 yes wherein # represents the point of attachment to -O- and ## represents the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0930] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0931] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2), Formula (IC), or Formula (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 3 It is C 1-3 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 3 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0932] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I'), Formula (IA), Formula (I-A2), Formula (IC), or Formula (I-C2)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, wherein the C 1-6 Alkyl is optionally substituted with one or more -OH. 3 It is C 1-3 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-3 Alkyl substituted, wherein the C 1-3 Alkyl is optionally substituted with one or more -OH. 3 Freedom to choose Composed of groups.

[0933] In some embodiments of a compound of Formula (I'), Formula (I), Formula (IA), Formula (I-A2), Formula (IB), or Formula (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 3-10 Cycloalkyl, where L 3 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. 3 It is C 3-8 Cycloalkyl, where L 3 The C 3-8 Cycloalkyl is optionally substituted with one or more -OH. 3 yes In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0934] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I'), Formula (IA), Formula (I-A2), Formula (IC), or Formula (I-C2)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is optionally replaced by one or more -OH or C 1-6 In some embodiments, L 3 is optionally substituted with one or more -OH or C 1-3 In some embodiments, L 3 yes

[0935] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0936] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-(CH 2 ) q OH, wherein q is an integer from 0 to 6. 4 Yes-(CH 2 ) q OH, wherein q is an integer from 0 to 2. In some embodiments, R 4 In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0937] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2), Formula (IC), or Formula (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-C 1-6 In some embodiments, R 4 Yes-C(O)-C 1-3 In some embodiments, R 4 is -C(O)CH 3 In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0938] In some embodiments of a compound of Formula (I), (IA), (I-A2), (IC), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 It is C 1-6 In some embodiments, R 5 It is C 1-3 In some embodiments, R 5is methyl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0939] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2), Formula (IC), or Formula (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 It is C 1-6 Alkyl, where R 5 The C 1-6 Alkyl is optionally substituted with one or more halo groups. 5 It is C 1-3 Alkyl, where R 5 The C 1-3 Alkyl is optionally substituted with one or more halo groups. 5 It is C 1-3 Alkyl, where R 5 The C 1-3 Alkyl is optionally substituted with one or more fluorine. 5 yes In some embodiments, R 5 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0940] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2), Formula (IC), or Formula (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 In some embodiments, R 5 is Cl or F. In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0941] In some embodiments, provided herein is a compound of Formula (I), Formula (IA), or Formula (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (ID):

[0942]

[0943] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m, p, R 1 , R 2 , R 3 , L 1 , L 3 and R 4 As defined for formula (I). In some variations, m, p, R 1 , R 2 , R 3 , L 1 , L 3 and R 4 As defined for a compound of formula (I') or formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0944] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is H. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0945] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 2 is C optionally substituted by one or more deuterium 1-6 In some embodiments, R 2 is C optionally substituted by one or more deuterium 1-3 In some embodiments, R 2 is methyl optionally substituted with one or more deuterium. 2 yes

[0946] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 1. In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0947] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 In some embodiments, R 1 is Cl. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0948] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is Cl or I.

[0949] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 is -CN. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0950] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 It is C 1-6 Alkyl, where R 1 The C 1-6 Alkyl is optionally substituted with one or more halo groups. 1 It is C 1-3 Alkyl, where R 1 The C 1-3 Alkyl is optionally substituted with one or more halo groups. 1 It is C 1-3 Alkyl, where R 1 The C 1-3 Alkyl is optionally substituted with one or more F. In some embodiments, R 1 is a methyl group, where R 1 The methyl group of is optionally substituted with one or more F. In some embodiments, R 1 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0951] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 1 is optionally replaced by one or more C 1-6 Alkyl substituted C 1-6 In some embodiments, L 1 is optionally replaced by one or more C 1-6 In some embodiments, L 1 Freedom to choose The group of components, where for each L 1 , # represents the point of attachment to -O- and ## represents the point of attachment to the rest of the molecule. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or their stereoisomers or tautomers or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0952] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0953] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is -O-. In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0954] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 In some embodiments, L 3 It is C1-3 In some embodiments, L 3 yes In some variations, the embodiments provided herein also apply to a compound of formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0955] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 1-6 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 3 It is C 1-3 Alkylene, where L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 In some embodiments, L 3 Freedom to choose Composed of groups.

[0956] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 3-10 In some embodiments, L 3 It is C 3-8 In some embodiments, L 3 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0957] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 3-10 Cycloalkyl, where L 3 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. 3 It is C 3-8 Cycloalkyl, where L3 The C 3-8 Cycloalkyl is optionally substituted with one or more -OH. 3 Freedom to choose In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or pharmaceutically acceptable salts of any of the foregoing or any variations or embodiments thereof.

[0958] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 It is C 3-10 Cycloalkyl, where L 3 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH. 3 It is C 3-8 Cycloalkyl, where L 3 The C 3-8 Cycloalkyl is optionally substituted with one or more -OH. 3 Freedom to choose Composed of groups.

[0959] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. 3 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0960] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L 3 is a 3-10 membered heterocyclyl. 3 is a 3-6 membered heterocyclyl. 3 Freedom to choose Composed of groups.

[0961] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-S(O) 2 -R a , where R a It is C 1-6 In some embodiments, R 4 Yes-S(O) 2 -R a , where R a It is C 1-3 In some embodiments, R 4 yes In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variations or embodiments thereof.

[0962] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-C(O)-N(R e ) 2 , where each R e is H. In some embodiments, R 4 Yes -C(O)-NH 2 In some variations, the embodiments provided herein also apply to compounds of Formula (I') or Formula (II) or stereoisomers or tautomers thereof or a pharmaceutically acceptable salt of any of the foregoing or any variations or embodiments thereof.

[0963] In some embodiments of a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is optionally replaced by one or more C 1-6 In some embodiments, R 4 is optionally replaced by one or more C 1-6 In some embodiments, R 4 is optionally replaced by one or more C 1-3 In some embodiments, R 4 is a 3-6 membered heterocyclyl optionally substituted with one or more methyl groups. 4 yes In some variations, the embodiments provided herein also apply to a compound of Formula (I') or Formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0964] In some embodiments of a compound of Formula (II) (such as a compound of Formula (I), Formula (IA), Formula (I-A2), or Formula (ID)), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 yes

[0965] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 is optionally replaced by one or more C 1-6 In some embodiments, R 4 is optionally replaced by one or more C 1-6 In some embodiments, R 4 is optionally replaced by one or more C 1-3 In some embodiments, R 4 is a 3-6 membered heterocyclyl optionally substituted with one or more methyl groups. 4 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0966] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-(CH 2 ) q OH, wherein q is an integer from 0 to 6. 4 Yes-(CH 2 ) q OH, wherein q is an integer from 0 to 2. In some embodiments, R 4 In some embodiments, R 4 Freedom to choose In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing or any variation or embodiment thereof.

[0967] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-N(R d ) 2 , where each R d are independently H. In some embodiments, R 4 Yes-NH 2 In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0968] In some embodiments of a compound of Formula (I'), Formula (IA), Formula (I-A2) or Formula (ID) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 4 Yes-P(O)(C 1-6 alkyl) 2 In some embodiments, R 4 Yes-P(O)(C 1-3 alkyl) 2 In some embodiments, R 4 Yes -P(O)(CH 3 ) 2 In some variations, the embodiments provided herein also apply to a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0969] In some embodiments, provided herein is a compound of Formula (I...

Claims

1. A compound of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy and C 1-6 The group consisting of alkyl groups, wherein R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups; R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein R 2 The C 1-6 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH; If it exists, then R 3 It is C 1-6 alkyl; L 1 It is C 1-6 Alkylene, wherein L 1 The C 1-6 The alkylene group is optionally substituted with one or more deuterium or C 1-6 alkyl substituted, and wherein The C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution; L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and Choose one of the following: (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein L 3 The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution, L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, where The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and L 3 The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substitution; X 1 and X 2 are each independently N or C(R 5 );and R 4 yes: (i)-S(O) 2 -R a ; (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution; (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a ,in R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (iv)-NS(O)-(C 1-6 alkyl) 2 , wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 Alkyl or 3-10 membered heterocyclic ring, wherein R e The 3-10 membered heterocyclic ring is optionally substituted by one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein The 3-10 membered heterocyclic group is optionally substituted with one or more halogen, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace, (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a replace, (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl), (viii) -CN, (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 6, (x)-C(O)-C 1-6 Alkyl, or (xi)-P(O)(C 1-6 alkyl) 2 ; or (2)L 3 does not exist; and X 1 and X 2 One of them is N or C (R 5 );and X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein The 5-10 membered heterocyclic group is optionally substituted by one or more R b Replace, where R b independently selected at each occurrence from -OH, halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 is substituted with a cycloalkyl radical, and wherein R b The C 1-6 The C of the alkyl group 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 alkyl or -OH substituted, and R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 alkyl substituted, and wherein R b The C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide, and The 5-20 membered heteroaryl group is optionally substituted by one or more R c Replace, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution, R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, and R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 alkyl substituted, and wherein R c The C of the 3-10 membered heterocyclic group 1-6 The alkyl group is further optionally substituted with one or more -OH groups; R a independently at each occurrence is: (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution, (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, where The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substituted, or (iv)NH(C 1-6 alkyl); R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo groups or -OH, and R 5 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups; X 3 is N or C(R 6 ); X 4 is N or C (R 7 ); and R 6 and R 7 Each is independently H or halo.

2. The compound according to claim 1, wherein the compound is a compound of formula (I'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy or C 1-6 The group consisting of alkyl groups, wherein R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups; R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein R 2 The C 1-6 The alkyl group is optionally substituted with one or more halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH; If it exists, then R 3 It is C 1-6 alkyl; L 1 It is C 1-6 Alkylene, where L 1 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 alkyl substituted, and wherein the C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution; L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and Choose one of the following: (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution, L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, and The 3-10 membered heterocyclyl is optionally substituted with one or more -OH; X 1 and X 2 are each independently N or C(R 5 );and R 4 yes: (i)-S(O) 2 -R a ; (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution; (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (iv)-NS(O)-(C 1-6 alkyl) 2 , wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 alkyl or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace, (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a replace, (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl), (viii) -CN, (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 6, (x)-C(O)-C 1-6 Alkyl, or (xi)-P(O)(C 1-6 alkyl) 2 ; or (2)L 3 does not exist; and X 1 and X 2 One of them is N or C (R 5 );and X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein The 5-10 membered heterocyclic group is optionally substituted by one or more R b Substitution, where R b is independently selected at each occurrence from halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 is cycloalkyl substituted, and Where R b The C 1-6 The C of the alkyl group 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 alkyl or -OH substituted, and R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 Alkyl substituted, and Where R b The C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH groups, and The 5-20 membered heteroaryl group is optionally substituted by one or more R c Substitution, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution, R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution, And R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substituted, and Where R c The C of the 3-10 membered heterocyclic group 1-6 The alkyl group is further optionally substituted with one or more -OH groups; R a independently at each occurrence is: (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution, (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, or (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substitution; R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein R 5 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups; and R 6 and R 7 Each is independently H or halo.

3. A compound according to claim 1 or claim 2, wherein the compound is a compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in: Choose one of the following: (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein L 3 The C 1-6 The alkylene group is optionally substituted with one or more C 1-6 Alkyl substituted, and The 3-10 membered heterocyclyl is optionally substituted with one or more -OH; X 1 and X 2 are each independently N or C(R 5 );and R 4 yes: (i)-S(O) 2 -R a ; (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution; (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (iv)-NS(O)-(C 1-6 alkyl) 2 , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 alkyl or a 3-10 membered heterocyclic ring, wherein the 3-10 membered heterocyclic ring is optionally substituted with one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, NH 2 、NH-S(O) 2 -R a or -S(O) 2 -R a replace, (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl or oxo substituted, (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl), (viii) -CN; or or (2)L 3 does not exist; and X 1 and X 2 One of them is N or C (R 5 );and X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein The 5-10 membered heterocyclic group is optionally substituted by one or more R b Substitution, where R b is independently selected at each occurrence from halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH or -S(O) 2 -C 1-6 Alkyl substituted, and R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH groups, and The 5-20 membered heteroaryl group is optionally substituted by one or more R c Substitution, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substituted, and R c The C 3-10 Cycloalkyl is optionally substituted with one or more -OH; R a independently at each occurrence is: (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substituted, or (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, or (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substitution; R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-6 The alkoxy group is optionally substituted with one or more halo groups; and R 6 and R 7 Each is independently H or halo.

4. The compound according to claim 1 or its stereoisomer or tautomer or a pharmaceutically acceptable salt of any of the foregoing, wherein L 2 is -O-, so that the compound is a compound of formula (IA): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

5. The compound according to any one of claims 1 to 4, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 1 or 2.

6. The compound according to any one of claims 1 to 5, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 It is H, C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-10 membered heterocyclic group, wherein R 2 The C 1-3 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-3 Alkoxy substituted, and R 2 The C 3-6 The cycloalkyl groups are optionally substituted with one or more -OH groups.

7. The compound of any one of claims 1 to 6, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m is 0, 1 or 2.

8. The compound according to any one of claims 1 to 7, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is halogen, -CN or -C 1-3 Alkyl, where R 1 The C 1-3 The alkyl group is optionally substituted with one or more halo groups.

9. The compound of any one of claims 1 to 8, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein p is 0 or 1.

10. The compound according to any one of claims 1 to 9, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 It is C 1-6 alkyl.

11. The compound according to any one of claims 1 to 10, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L 1 It is C 1-3 Alkylene, where L 1 The C 1-3 The alkylene group is optionally substituted with one or more deuterium or C 1-3 Alkyl substituted, wherein the C 1-3 The alkyl group is optionally replaced by -OH or C 1-3 Alkoxy substitution.

12. A compound according to any one of claims 1 to 11, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L 1 Freedom to choose The group of components, where for each L 1 , * indicates the same as L 2 and ** denotes the point of attachment to the rest of the molecule.

13. A compound according to any one of claims 1 to 12, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L 2 It's O.

14. A compound according to any one of claims 1 to 13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L 3 Does not exist.

15. A compound according to any one of claims 1 to 13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L 3 Yes-O-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein L 3 The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution, L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, where The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and L 3 The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substitution.

16. A compound according to any one of claims 1 to 13 and 15, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L 3 Choose from -O-, Composed of groups.

17. A compound according to any one of claims 1 to 16, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 YesS(O) 2 -R a , 5-10 membered heteroaryl, -N(R d ) 2 、-NS(O)-(C 1-3 alkyl) 2 、-C(O)-N(R e ) 2 , 3-6 membered heterocyclic group, -S(O)(NC 1-3 Alkyl)-(C 1-3 alkyl), -CN, -OH, -C(O)-C 1-3 Alkyl or -P(O)(C 1-3 alkyl) 2 ,in R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-3 Alkyl substituted, and The 3-6 membered heterocyclic group is optionally substituted with one or more -OH, oxo, C 1-3 Alkyl or -S(O) 2 -R a replace.

18. The compound according to claim 17, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R a It is C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-10 membered heterocyclic group, wherein R a The C 1-6 The alkyl group is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution, R a The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and R a The 3-10 membered heterocyclic group is optionally substituted by one or more C 1-6 Alkyl substitution.

19. The compound according to claim 17, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a , where R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and wherein R a It is C 1-6 alkyl.

20. The compound of claim 17 or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, wherein R e In each occurrence, it is independently H, C 1-6 alkyl or a 3-10 membered heterocyclic ring, wherein the 3-6 membered heterocyclic ring is optionally substituted with one or more oxo groups.

21. The compound according to claim 17 or its stereoisomer or tautomer or a pharmaceutically acceptable salt of any of the foregoing, wherein two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein the 3-10 membered heterocyclic group is optionally substituted by one or more halo, oxo, -OH, -NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a Substitution, where R a It is C 1-6 alkyl.

22. A compound according to any one of claims 1 to 21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 and X 2 Each of them is C(R 5 ).

23. A compound according to any one of claims 1 to 21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 and X 2 Each of is N.

24. A compound according to any one of claims 1 to 21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 and X 2 One of them is N and the other is C (R 5 ).

25. A compound according to any one of claims 1 to 21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 and X 2 One of them is N or CR 5 , and X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a b Substituted 5-10 membered heterocyclic group.

26. The compound of claim 25 or its stereoisomer or tautomer or a pharmaceutically acceptable salt of any of the foregoing, wherein R b independently selected at each occurrence from -OH, halo, oxo, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein R b The C 1-3 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-3 Alkyl or C 3-6 is substituted with a cycloalkyl group, and wherein R b The C 1-3 The C of the alkyl 3-6 The cycloalkyl group is further optionally substituted with one or more C 1-3 Alkyl or -OH substituted, and R b The C 3-6 The cycloalkyl group is optionally substituted with one or more -OH, C 3-6 Cycloalkyl or C 1-3 alkyl substituted, and wherein R b The C 3-6 The C of the cycloalkyl group 1-3 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide.

27. A compound according to any one of claims 1 to 21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 and X 2 One of them is N or CR 5 , and X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a c Substituted 5-10 membered heteroaryl.

28. The compound of claim 27 or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, wherein R c independently selected at each occurrence from halogen, C 1-3 Alkyl, -C(O)-C 1-3 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-3 alkyl), -C(O)-N(C 1-3 alkyl) 2 、-S(O) 2 -R a , C 3-6 A group consisting of a cycloalkyl group and a 3-6 membered heterocyclic group, wherein R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-3 Alkyl substitution, R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-3 Alkyl substituted, and R c The 3-6 membered heterocyclic group is optionally substituted by one or more -OH or C 1-3 alkyl substituted, and wherein R c The C of the 3-6 membered heterocyclic group 1-3 The alkyl group is further optionally substituted with one or more -OH groups.

29. A compound according to any one of claims 1 to 28, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 5 is independently H, halo, -CN, 3-6 membered heterocyclyl, C 1-3 Alkyl or C 1-3 Alkoxy, where R 5 The C 1-3 The alkyl group is optionally substituted with one or more halo or -OH groups, and wherein the C 1-3 The alkoxy group is optionally substituted with one or more halo groups.

30. The compound of claim 1 or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing is selected from Compounds 1-472 of Table 1.

31. A method for preparing a compound of formula (II) according to claim 1 or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, the method comprising the step of reacting the following two compounds: a compound of formula (II'-A): in: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy and C 1-6 The group consisting of alkyl groups, wherein R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups; R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein R 2 The C 1-6 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH; If it exists, then R 3 It is C 1-6 alkyl; and: Compound of formula (II'-B): in: Dashed lines represent single or double bonds; Y 1 Is a halogen, oxo or sulfonate L 1 It is C 1-6 Alkylene, wherein L 1 The C 1-6 The alkylene group is optionally substituted with one or more deuterium or C 1-6 alkyl substituted, and wherein The C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substitution; L 2 is O or N (R x ), where R x Is H or C 1-6 Alkyl; and Choose one of the following: (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein L 3 The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution, L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, where The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and L 3 The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substitution; X 1 and X 2 are each independently N or C(R 5 );and R 4 yes: (i)-S(O) 2 -R a ; (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution; (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a ,in R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (iv)-NS(O)-(C 1-6 alkyl) 2 , wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 Alkyl or 3-10 membered heterocyclic ring, wherein R e The 3-10 membered heterocyclic ring is optionally substituted by one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein The 3-10 membered heterocyclic group is optionally substituted with one or more halogen, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace, (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a replace, (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl), (viii) -CN, (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 6, (x)-C(O)-C 1-6 Alkyl, or (xi)-P(O)(C 1-6 alkyl) 2 ; or (2)L 3 does not exist; and X 1 and X 2 One of them is N or C (R 5 );and X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein The 5-10 membered heterocyclic group is optionally substituted by one or more R b Replace, where R b independently selected at each occurrence from -OH, halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 is substituted with a cycloalkyl radical, and wherein R b The C 1-6 The C of the alkyl 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 alkyl or -OH substituted, and R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 alkyl substituted, and wherein R b The C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide, and The 5-20 membered heteroaryl group is optionally substituted by one or more R c Replace, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution, R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, and R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 alkyl substituted, and wherein R c The C of the 3-10 membered heterocyclic group 1-6 The alkyl group is further optionally substituted with one or more -OH groups; R a independently at each occurrence is: (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution, (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, where The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substituted, or (iv)NH(C 1-6 alkyl); R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo groups or -OH, and R 5 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups; X 3 is N or C (R 6 ); X 4 is N or C (R 7 ); and R 6 and R 7 are each independently H or halo; To obtain the compound of formula (II) or its stereoisomer or tautomer or a pharmaceutically acceptable salt of any of the foregoing.

32. The method of claim 31, wherein the compound of claim 1 is prepared by the steps comprising: a) alkylating an amine of formula (II'-A) with an alkyl halide or sulfonate compound of formula (II'-B) in the presence of an inorganic base; or b) reductive amination of a ketone of the formula (II'-B) with an amine of the formula (II'-A).

33. The method of claim 32, wherein the inorganic base is selected from the group consisting of potassium carbonate and sodium bicarbonate.

34. The process of claim 32, wherein the reductive amination is carried out with sodium triacetoxyborohydride, titanium tetrapropoxide and acetic acid.

35. A method for preparing a compound of formula (II) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing according to claim 1, the method comprising the step of reacting the following two compounds: a compound of formula (II'-C): in: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; If it exists, then R 1 is independently selected at each occurrence from halo, -CN, C 1-6 Alkoxy and C 1-6 The group consisting of alkyl groups, wherein R 1 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups, and R 1 The C 1-6 The alkyl group is optionally substituted with one or more halo groups; R 2 It is H, C 1-6 Alkyl, C 3-10 Cycloalkyl or 3-15 membered heterocyclic group, wherein R 2 The C 1-6 The alkyl group is optionally substituted with one or more deuterium, halo, -OH, -NH 2 or C 1-6 Alkoxy substituted, and R 2 The C 3-10 Cycloalkyl is optionally substituted with one or more -OH; If it exists, then R 3 It is C 1-6 alkyl; L 1 It is C 1-6 Alkylene, wherein L 1 The C 1-6 The alkylene group is optionally substituted with one or more deuterium or C 1-6 alkyl substituted, and wherein The C 1-6 The alkyl group is further optionally substituted with one or more -OH or C 1-6 Alkoxy substituted; and Y 2 Is a halogen, -OH or -NH 2 ; and: Compound of formula (II'-D): in: Y 3 is -OH or -NH(R x ), where each R x independently H or C 1-6 Alkyl; and Choose one of the following: (1)L 3 Does not exist or is O, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group or C 1-6 Alkylene, wherein L 3 The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substitution, L 3 The C 1-6 The alkylene group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, where The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, and L 3 The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 Alkyl substitution; X 1 and X 2 are each independently N or C(R 5 );and R 4 yes: (i)-S(O) 2 -R a ; (ii) a 5-20 membered heteroaryl group, wherein R 4 The 5-20 membered heteroaryl group is optionally substituted by one or more C 1-6 Alkyl substitution; (iii)-N(R d ) 2 , where R d In each occurrence, it is independently H, C 1-6 Alkyl or -S(O) 2 -R a ,in R d The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (iv)-NS(O)-(C 1-6 alkyl) 2 , wherein the C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (v)-C(O)-N(R e ) 2 , where R e In each occurrence, it is independently H, C 1-6 Alkyl or 3-10 membered heterocyclic ring, wherein R e The 3-10 membered heterocyclic ring is optionally substituted by one or more oxo groups, or two R e Together with the nitrogen to which they are attached, they form a 3-10 membered heterocyclic group, wherein The 3-10 membered heterocyclic group is optionally substituted with one or more halogen, oxo, -OH, NH 2 、-NH-S(O) 2 -R a or -S(O) 2 -R a replace, (vi) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl, -OH, oxo or -S(O) 2 R a replace, (vii)-S(O)-N(C 1-6 Alkyl)-(C 1-6 alkyl), (viii) -CN, (ix)-(CH 2 ) q OH, wherein q is an integer from 0 to 6, (x)-C(O)-C 1-6 Alkyl, or (xi)-P(O)(C 1-6 alkyl) 2 ; or (2)L 3 does not exist; and X 1 and X 2 One of them is N or C (R 5 );and X 1 and X 2 The other one is N or C, and the N or C and R 4 and the atoms to which they are attached together form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein The 5-10 membered heterocyclic group is optionally substituted by one or more R b Replace, where R b independently selected at each occurrence from -OH, halo, oxo, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R b The C 1-6 The alkyl group is optionally substituted with one or more halo, OH, -S(O) 2 -C 1-6 Alkyl or C 3-10 is substituted with a cycloalkyl radical, and wherein R b The C 1-6 The C of the alkyl group 3-10 The cycloalkyl group is further optionally substituted with one or more C 1-6 alkyl or -OH substituted, and R b The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH, C 3-10 Cycloalkyl or C 1-6 alkyl substituted, and wherein R b The C 3-10 The C of the cycloalkyl group 1-6 The alkyl group is further optionally substituted with one or more -OH, deuterium or halide, and The 5-20 membered heteroaryl group is optionally substituted by one or more R c Replace, where R c independently selected at each occurrence from halogen, C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-NH 2 、-C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 、-S(O) 2 -R a , C 3-10 A group consisting of a cycloalkyl group and a 3-10 membered heterocyclic group, wherein R c The C 1-6 The alkyl group is optionally substituted with one or more -S(O) 2 -C 1-6 Alkyl substitution, R c The C 3-10 The cycloalkyl group is optionally substituted with one or more -OH or C 1-6 Alkyl substituted, and R c The 3-10 membered heterocyclic group is optionally substituted by one or more -OH or C 1-6 alkyl substituted, and wherein R c The C of the 3-10 membered heterocyclic group 1-6 The alkyl group is further optionally substituted with one or more -OH groups; R a independently at each occurrence is: (i)C 1-6 Alkyl, which is optionally substituted with one or more halo, -OH, -S(O) 2 -C 1-6 Alkyl or -N(C 1-6 alkyl)-C(O)-C 1-6 Alkyl substitution, (ii)C 3-10 Cycloalkyl, which is optionally substituted with one or more -OH, -C(O) 2 -C 1-6 Alkyl, -C(O)-NH(C 1-6 alkyl), -C(O)-N(C 1-6 alkyl) 2 or -C(O)-C 3-10 Heterocyclic or C 1-6 Alkyl substituted, where The C 1-6 The alkyl group is optionally substituted with one or more -OH groups, (iii) a 3-10 membered heterocyclic group, which is optionally substituted by one or more C 1-6 Alkyl substituted, or (iv)NH(C 1-6 alkyl); R 5 is independently H, halo, -CN, 3-10 membered heterocyclyl, C 1-6 Alkyl or C 1-6 Alkoxy, where R 5 The C 1-6 The alkyl group is optionally substituted with one or more halo groups or -OH, and R 5 The C 1-6 The alkoxy group is optionally substituted with one or more halo groups; X 3 is N or C(R 6 ); X 4 is N or C(R 7 ); and R 6 and R 7 are each independently H or halo; To obtain the compound of formula (II) or its stereoisomer or tautomer or a pharmaceutically acceptable salt of any of the foregoing.

36. The method of claim 35, wherein the compound of claim 1 is prepared by the steps comprising: a) coupling an alcohol compound of formula (II'-C) with a phenol compound or a heterocyclic variant of formula (II'-D) under Mitsunobu-type reaction conditions; or b) reacting an alkyl halide compound of formula (II'-C) with a phenol or amine compound of formula (II'-D) in the presence of a catalyst.

37. The method of claim 36, wherein the Mitsunobu-type reaction conditions comprise coupling an alcohol compound of formula (II'-C) with a phenol compound or heterocyclic variant of formula (II'-D) in the presence of triphenylphosphine and diisopropyl azodicarboxylate.

38. The method of claim 37, wherein the catalyst is silver oxide or potassium carbonate.

39. A pharmaceutical composition comprising (i) a compound according to any one of claims 1 to 30 or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

40. A method of modulating APOL1 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of any one of claims 1-30 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 39.

41. A method of inhibiting APOL1 in a cell, the method comprising exposing the cell to a composition comprising an effective amount of a compound of any one of claims 1-30 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 39.

42. A method of treating an APOL1-mediated disease, condition or disorder in a subject in need thereof, the method comprising administering to the subject a compound of any one of claims 1-30 or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39.

43. The method of claim 42, wherein the disease, disorder or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), kidney disease due to hypertension, human immunodeficiency virus-associated nephropathy (HIVAN), sickle cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19-associated nephropathy, preeclampsia, and sepsis.

44. The method of claim 42 or claim 43, wherein the disease, disorder or condition is kidney disease.

45. The method of any one of claims 40-44, wherein the disease, disorder or condition is chronic kidney disease (CKD).

46. ​​A method of delaying the development of an APOL1-mediated disease, disorder or condition, the method comprising administering to an individual at risk of developing an APOL1-mediated disease, disorder or condition a compound of any one of claims 1-30 or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39.

47. The method of claim 46, wherein the APOL1 -mediated disease, disorder or condition is kidney disease.

48. The method of claim 46 or claim 47, wherein the APOL1 -mediated disease, disorder or condition is chronic kidney disease.

49. The method of claim 46, wherein the APOL1-mediated disease, disorder or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), kidney disease caused by hypertension, human immunodeficiency virus-associated nephropathy (HIVAN), sickle cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19-associated nephropathy, preeclampsia, and sepsis.

50. The method of any one of claims 40-49, wherein the individual has an APOL1 mutation.

51. The method of claim 50, wherein the APOL1 mutation is a gain-of-function mutation.

52. The method of any one of claims 42-51, wherein a therapeutically effective amount of a compound of any one of claims 1-30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39 is administered.

53. A kit comprising (i) a compound of any one of claims 1-30 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39, and (ii) instructions for use in treating an APOL1-mediated disease, disorder or condition in a subject in need thereof.

54. The kit of claim 53, wherein the disease, disorder or condition is kidney disease.

55. The kit of claim 53 or claim 54, wherein the disease, disorder or condition is chronic kidney disease (CKD).

56. The kit of any one of claims 53-55, wherein the disease, disorder or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), kidney disease due to hypertension, human immunodeficiency virus-associated nephropathy (HIVAN), sickle cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19-associated nephropathy, preeclampsia, and sepsis.

57. The kit of any one of claims 53-56, wherein the individual has an APOL1 mutation.

58. The kit of claim 57, wherein the APOL1 mutation is a gain-of-function mutation.

Citation Information

Cited By

  • Apol1 inhibitors and methods of use

    EP4465982A4